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1. INTRODUCTION  
 
1. 1.  Peroxiredoxins 
 
  Peroxiredoxins (Prxs) (EC 1.11.1.15) are multifunctional antioxidant 
thioredoxin-dependent peroxidases that have been ubiquitously identified in 
organisms ranging from bacteria to mammals. Prx proteins are abundantly expressed 
in mammalian cells and are primarily localized at the sites of peroxide production 
including cytosol, mitochondria and peroxisomes (Immenschuh and Baumgart-Vogt, 
2005).  
 
1.1.1. Classification of Prxs 
 
 Thus far, six isoforms of Prxs have been identified in mammals and are 
classified into three subgroups based on the content and usage of highly conserved 
cysteinyl residues in the catalytic site. Typical 2-cysteine Prxs contain N-terminal and 
C-terminal cysteine residues, and both are required for the catalytic function (Prx I – 
IV). Atypical 2-cysteine (Prx V) and 1-cysteine (Prx VI) Prxs contain only the N-
terminal cysteine, but atypical 2-cysteine Prxs require an additional cysteine for 
catalytic activity (Figure 1).  
 
 
 
   
 
  
                                     
       
Figure 1. Classification of Prxs 
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1.1.2.  Prxs - mechanism of action 
 
 Prx-mediated peroxidase reaction is a two step mechanism and is similar for 
all Prxs. The cysteinyl residues present in the active site are redox sensitive and 
undergo a cycle of peroxide-dependent oxidation and thiol-dependent reduction 
during the catalytic process (Rhee et al., 2005). In the first step, the catalytic cysteine 
residues attack the peroxide substrate and are oxidized. The attacked peroxides are 
converted into water and alcohol. In the second step, the oxidized Prxs are reduced 
and converted into the active form by electron donors such as thioredoxin and 
sulfiredoxin (Wood et al., 2003) (Figure 2).  
 
Peroxide detoxification 
 
 
 
               Thioredoxin 
               Sulfiredoxin 
 
Figure 2. A simplified mechanism of the Prx-mediated enzyme reaction 
 
1.1.3. Physiological role of Prxs 
 
Reactive oxygen species (ROS) are chemical species that are formed upon 
incomplete reduction of oxygen. The major forms of ROS are oxygen ions, free 
radicals and peroxides. Prxs play a significant role in intracellular peroxide and 
peroxynitrite detoxification. The antioxidant properties of Prx proteins have been 
confirmed in studies demonstrating that mice with genetic deficiency of various Prxs 
are highly susceptible to oxidative stress-mediated injury. In addition, recent studies 
have shown that Prx activities are involved in various cellular functions such as 
peroxide-dependent signaling, regulation of cell cycle, proliferation, differentiation 
and apoptosis (Immenschuh and Baumgart-Vogt, 2005).  
 
 
 
Prx [reduced]  Prx [oxidized]  
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1.1.4.   Peroxiredoxin I (Prx I) 
 
 Prx I is the best characterized isoform of the known  mammalian Prxs. Prx I 
gene expression is up-regulated by various oxidative stress stimuli and may serve as 
an antioxidant cellular response against stress-related toxicity (Immenschuh et al., 
1995, Ishii et al., 2000, Li et al., 2002). Mice with targeted disruption of the Prx I 
gene have been shown to progressively accumulate intracellular ROS and to exhibit 
an increased incidence of various malignancies (Neumann et al., 2003, Egler et al., 
2005, Neumann and Fang, 2007). More recently, Prx I has also been shown to have 
anti-inflammatory functions in an experimental model of atherosclerosis (Kisucka et 
al., 2008). Therefore, it is conceivable that Prx I is not only involved in the regulation 
of cellular redox homeostasis, but may also have potent anti-tumorigenic and anti-
inflammatory functions.  
 
1.1.5.  Regulation and signal transduction of Prx I gene expression 
 
 Regulation of Prx I gene expression by various oxidative stimuli is mediated 
via a highly conserved cis-acting antioxidant response element (ARE) (Ishii et al., 
2000, Kim et al., 2007). The ARE, also known as stress response element (StRE) has 
been identified as a crucial regulatory element (RE) for the induction of various 
detoxifying enzymes and stress proteins. Redox-regulated transcription factors (TFs) 
such as nuclear factor-erythroid-2 related factor 2 (Nrf2) and activator protein-1 (AP-
1) have previously been shown to target the StRE (Nguyen et al., 2003). In line with 
this notion, induction of Prx I gene expression by oxidative stress stimuli has 
previously been shown to be mediated via a StRE in a Nrf2- and AP-1-dependent 
manner (Immenschuh and Baumgart-Vogt, 2005). In addition, various studies 
suggested that the Prx I gene is also regulated via posttranslational mechanisms such 
as protein phosphorylation, redox-dependent oligomerization, proteolysis and 
modification of ligand binding (Wood et al., 2003). Activation of signaling pathways 
such as protein kinase C (PKC) and p38 mitogen-activated protein kinase (MAPK) 
has been shown to mediate Prx I gene activation (Hess et al., 2003).  
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1.2. Heme oxygenase  
  
 Heme oxygenase (HO) (EC 1.14.99.3) is a microsomal enzyme that catalyzes 
the first and rate-limiting step of oxidative heme (Fe-protoporphyrin-IX) degradation. 
HO cleaves the tetrapyrrole ring of heme into equimolar amounts of biliverdin-IXα, 
carbon monoxide (CO) and iron (Fe).  
Biliverdin-IXα is subsequently converted into bilirubin-IX via a NAD(P)H-dependent 
reductase (Maines, 1997) (Figure 3).  
 
 
 
  
  
 
 
 
 
 
Figure 3. Catalytic deg
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functions, an increasing body of evidence suggests important biological functions to 
the products of the HO enzyme reaction. In particular, CO and biliverdin/bilirubin 
have been shown to exert unique antioxidant, signaling and immunomodulatory 
functions (Otterbein et al., 2003). 
 
1.2.3. Heme oxygenase-1 (HO-1) 
 
 HO-1 is the inducible isoform of HO and was initially identified in 1968 
(Tenhunen et al., 1968). HO-1, also known as 32-kDa heat shock protein, is barely 
expressed under basal conditions in most cells and tissues, but is highly up-regulated 
in response to a host of stimuli including both chemical and physical stress agents 
(Ferrandiz and Devesa, 2008). Up-regulation of HO-1 during oxidative insults has 
been shown to have cytoprotective effects, in particular in immune cells such as 
monocytes (Tracz et al., 2007). In addition, recent studies in HO-1 knockout mice 
(Poss and Tonegawa, 1997) and a human case of HO-1 genetic deficiency (Yachie et 
al., 1999) emphasized the antioxidant, anti-inflammatory and immunomodulatory 
functions of HO-1 (Table 1). 
 
Table 1. Phenotypical alterations in human and mouse genetic HO-1 deficiency 
Findings Human Mouse 
 
Intrauterine death 
Growth failure 
Anemia  
Fragmentation  
Iron binding capacity 
Ferritin 
Iron deposition 
 
Stillbirth, abortion 
+ 
+ 
+ 
Increased 
Elevated 
+ 
 
20% birth rate 
+ 
+ 
? 
Increased 
Elevated 
+ 
Hepatomegaly 
Splenomegaly 
Lymph node swelling 
Leukocytosis 
Thrombocytosis 
Coagulation abnormality 
Endothelial injury 
Hyperlipidemia 
+ 
Asplenia 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
? 
? 
? 
? 
Adopted from Yachie et al., 1999 
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1.2.4. Gene regulation and signal transduction pathways of HO-1 
             
 HO-1 gene activation by most stimuli is predominantly regulated at the 
transcriptional level. A comprehensive analysis of various mammalian HO-1 gene 
promoters has revealed several REs, which serve as binding sites for a variety of TFs. 
In addition, two important enhancer sequences have been identified in the distal 5'- 
flanking region of the human and mouse HO-1 gene promoters at – 4 kb and –10 kb. 
These enhancer sequences contain multiple StREs and are essential for the basal and 
inducible HO-1 gene expression (Ryter et al., 2006). Considerable structural and 
spatial differences, however, have been found between rodent and human HO-1 gene 
promoters, which may explain the species-specific regulation of HO-1 gene 
expression (Exner et al., 2004, Naidu et al., 2008).  
It is generally accepted that the basic leucine zipper (bZIP) TF Nrf2 is the 
major regulator of oxidative stress-dependent induction of HO-1 gene expression. 
Nevertheless, other TFs such as AP-1, heat-shock factor (HSF) and nuclear factor-κB 
(NF-κB) have also been shown to play a significant role for the regulation of HO-1 
expression in response to various stimuli (Alam and Cook, 2007). 
Accumulating evidence indicates that HO-1 induction is mediated via 
activation of multiple signaling pathways. In particular, a major regulatory role for 
HO-1 gene expression has been ascribed to the MAPK p38, extracellular signal-
regulated kinase (ERK) and c-jun N-terminal kinase (JNK). Recent studies, however, 
have reported significant variations among the signaling cascades that regulate HO-1 
expression in a cell-, tissue- or inducer-specific manner (Ryter et al., 2006). 
 
1.3.  Regulation of Prx I and HO-1 gene expression in monocytes – Objective of 
the study 
 
  Mononuclear phagocytes (monocytes, macrophages) play a critical role for the 
regulation of inflammation. Mononuclear phagocytes are activated in response to 
tissue injury or microorganisms and generate substantial amounts of intracellular 
ROS, which serve potent microbicidal and signaling functions (Beaman and Beaman, 
1984).  
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The unique defensive properties of these cells would cause irreversible tissue 
damage, if they would not be controlled in a specific manner (Richard and Johnston, 
1988). Therefore, endogenous antioxidant and anti-inflammatory protective 
mechanisms play a major physiological role in these cells. 
Evidence has accumulated that Prx I and HO-1 gene expression is up-
regulated by oxidative stress and proinflammatory stimuli in monocytic cells (Abbas 
et al., 2008, Wijayanti et al., 2004). Since Prx I and HO-1 have potent antioxidant and 
immunomodulatory functions, up-regulation of these two genes in monocytic cells 
may have beneficial effects during oxidative stress-related disorders (Figure 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Rationale of the study 
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The proinflammatory mediator lipopolysaccharide (LPS) and the PKC 
activator phorbol myristate acetate (PMA), also termed 12-O-tetradecanoyl-phorbol-
13-acetate (TPA), are prototypical activators of monocytic cells. Both, PMA and LPS, 
have previously been shown to increase the generation of ROS in a NAD(P)H 
oxidase-dependent manner in monocytic cells (Datta et al., 2000, Park et al., 2004). In 
addition, treatment with PMA and LPS has previously been shown to up-regulate HO-
1 and Prx I gene expression in monocytic cells (Muraosa et al., 1993, Hess et al., 
2003). Understanding the regulatory networks of these two genes in monocytes may 
help to prevent and treat chronic inflammatory disorders, which may ultimately lead 
to cancer (Karin et al., 2006). Therefore, the objective of the present studies was to 
elucidate the molecular mechanisms and signaling pathways that regulate gene 
expression of Prx I and HO-1 in response to PMA and LPS in monocytic cells. The 
primary objective of the studies was as follows: 
 
1.3.1. Specific aim I: To elucidate the signaling pathway(s) that regulate(s) Prx I gene 
expression in response to PMA and LPS in monocytic cells.  
     It is shown that PMA and LPS induced Prx I gene expression in RAW264.7 
monocytic cells. Treatment with LPS, however, inhibited PMA-dependent induction 
of Prx I gene expression indicating cross talk of signaling pathways that are activated 
by these stimuli. The LPS-dependent inhibition of Prx I gene activation by PMA is 
mediated via a transcriptional mechanism that involves a ‘non-classical’ activation of 
the TF NF-κB and the non-receptor tyrosine kinase Bruton’s tyrosine kinase (Btk) 
(Paper I). 
 
1.3.2. Specific aim II: To elucidate the signaling pathway(s) that induce HO-1 gene 
expression by PMA in monocytes, and the specific role of p38 MAPK for the 
regulation of HO-1 gene expression. 
It is demonstrated that HO-1 gene expression was induced by PMA in 
RAW264.7 monocytic cells and was transcriptionally regulated via a newly identified 
κB element of the rat HO-1 proximal promoter that is a target of the NF-κB subunit 
p65/RelA.  
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An IκB kinase (IKK)-independent, atypical NF-κB pathway mediated PMA-
dependent induction of HO-1 gene expression via activation of p38 MAPK and CK2 
(Paper II).  
HO-1 gene expression was up-regulated by genetic deficiency or 
pharmacological inhibition of p38 MAPK. Induction of HO-1 gene expression by p38 
inhibition is transcriptionally regulated via the stress-inducible TF Nrf2 (Paper III). 
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2. MATERIALS and METHODS 
 
A detailed description of the materials and methods are given in the respective 
papers of this thesis. All the materials that were used for the study are of reagent 
grade and were obtained from different suppliers as indicated. This chapter briefly 
summarizes the methodology applied in various parts of the experimental studies.  
  
Plasmid preparations: Competent Escherichia. coli were transformed with plasmid 
DNA and cultured according to standard protocols. Plasmid preparations were 
performed using QIAGEN endotoxin-free kits. DNA concentrations were determined 
by the measurement of absorbance at 260 and 280 nm.  
Generation of luciferase promoter constructs: Luciferase reporter gene constructs 
used in the study were generated using standard molecular cloning techniques or 
received as gifts from various sources cited accordingly. Mutated reporter gene 
constructs were generated using QuikChange XL site-directed mutagenesis kit 
(Stratagene) according to the manufacturer’s instructions. Insert orientation or 
mutations in the plasmids were verified by DNA sequencing in both directions. 
Transient transfection and luciferase assay: Transfection of plasmid DNA into 
cells was performed using a liposome-based transfection reagent FuGENE® 6 
(Roche). Plasmid DNA at amounts of 0.5 to 1 µg and for contransfection experiments 
0.1 to 1.5 µg was added to 2 to 3 µl of transfection reagent in serum free medium. The 
DNA-lipid complex was added dropwise to the cell cultures in complete media. After 
24 h of transfection or treatment with various stimuli before harvesting, cells were 
lysed using cell culture lysis reagent (Promega). The lysate was assayed for luciferase 
activity using the Dual luciferase assay kit (Promega). Relative light units of Firefly 
luciferase activity were normalized with Renilla luciferase activity.  
Electrophoretic mobility shift assay (EMSA):  The DNA-protein complexes were 
resolved on 6 % native polyacrylamide gels and blotted onto nylon membranes 
(Pierce). The interactions between biotin-labeled DNA and proteins were detected 
with a non-radioactive LightShift chemiluminescent EMSA kit (Pierce) according to 
the manufacturer’s instructions. 
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 Cell culture: All cell lines or primary cells used in the study were cultured in 
suitable growth media supplemented with 10 % FCS, 100 U/ml penicillin and 100-   
µg/ml streptomycin. Cell cultures were maintained under air/CO2 (19:1) at 100 % 
humidity. 
Western blotting: Protein concentration was determined with the BCA protein assay 
kit (Pierce). Proteins were separated on 12 % SDS-polyacrylamide gels and electro- 
blotted onto polyvinylidene difluoride membranes. Membranes were blocked either 
with 5 % fat-free milk buffer or 5 % bovine serum albumin, and probed with 
corresponding primary and secondary antibodies at the concentrations indicated by 
the manufacturers. The ECL chemiluminescent detection system was applied for 
detections and the signals were visualized either by exposure to X-ray films or with 
the Fluorchem FC2 gel documentation system.  
Subcellular fractionation: Cells were washed twice in ice-cold PBS, and incubated 
in 200 µl of ice-cold homogenizing buffer. Thereafter, cells were scraped from the 
dishes, dounce-homogenized with 50 strokes and centrifuged at 2500 x g for 20 min at 
4°C to separate nuclei from cytosol. The supernatant was collected as cytosolic 
fraction, and the pelleted nuclear fraction was washed twice in homogenizing buffer 
and incubated in 100 µl extraction buffer. Samples were rocked at 4°C for 20 min and 
centrifuged at 12,000 x g for 10 min. This fraction was collected as nuclear extract 
(NE). All fractions were brought to equal volumes and protein content was determined 
for the cytosol and nuclear extract fractions (Buffer compositions see Paper III). 
Measurement of ROS: Intracellular generation of ROS was detected with 
dihydroethidium (DHE) dye (Invitrogen). After stimulation, cells were incubated with 
5 µM DHE for 20 min, washed with PBS and the levels of ROS were determined with 
a FACScalibur flow cytometer. DHE-detectable superoxide anion (FL2-H) fluorescent 
signals were displayed as histograms.  
Statistics:  Quantitative data obtained either from Western blot analysis or luciferase 
assays were analyzed by Student’s t test and presented as mean values ± S.E. from at 
least three independent experiments. A value of p ≤ 0.05 was considered as 
statistically significant.  
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3. RESULTS and DISCUSSION 
 
The two major aspects of the thesis are presented in three original articles. The 
first paper demonstrates the regulatory role of the TF NF-κB for Prx I gene expression 
by PMA and LPS. The second paper identified an atypical NF-κB pathway, which 
mediated the PMA-dependent induction of HO-1 gene expression via a newly 
identified functional κB element of the rat HO-1 promoter. The third paper deals with 
an unexpected up-regulation of HO-1 gene expression by inhibition of the p38 MAPK 
pathway, which was mediated via the TF Nrf2. 
 
3.1. Regulation of Prx I gene expression by PMA and LPS in monocytic cells  
(Paper I) 
 
The monocyte activators PMA or LPS alone up-regulated Prx I gene 
expression in RAW264.7 monocytic cells. Unexpectedly, simultaneous treatment of 
LPS inhibited Prx I gene activation by PMA. This inhibitory effect of LPS, which 
appears to be cell-specific for monocytes, was not observed for gene regulation of 
Cox-2 and TNF-α, both of which are also known to be induced by PMA and LPS 
(Figure 1, paper I). A similar inhibitory pattern of LPS has previously been reported 
for the expression of the epoxide hydrolase and glutathione S-transferase genes (Choi 
et al., 1998).  
LPS-dependent inhibition of Prx I gene activation by PMA occurred on the 
transcriptional level and was regulated via the TF NF-κB, which binds to a newly 
identified Prx-κB site (Figures 3 and 4, paper I). Various oxidative stress stimuli and 
inflammatory mediators activate the classical NF-κB pathway, which includes 
stimulus-coupled phosphorylation of the IκB-kinase complex and phosphorylation of 
IκB. Phosphorylation of IκB leads to its degradation via the proteasome and, 
subsequently, p65 is translocated into the nucleus (Chen et al., 2004).  
This pathway, however, does not seem to be involved in the regulation of LPS-
dependent repression of Prx I gene activation by PMA, because overexpression of 
dominant negative IκB had no effect on the inhibitory effect of LPS. In addition, 
simultaneous treatment of LPS did not alter PMA-dependent phosphorylation of IκB 
(Figure 5, paper I).  
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These observations led to the conclusion that a ‘non-classical’ mode of NF-κB 
activation is involved in this regulatory mechanism. In line with this conclusion, an 
IκB-independent activation of NF-κB, including phosphorylation of p65 at regulatory 
serine 276, was involved in the regulation of inhibition of Prx I gene induction by 
LPS. Treatment with PMA induced phosphorylation of p65 at serine 276, which was 
markedly attenuated by simultaneous exposure to LPS. In addition, functional studies 
with Gal4-p65 fusion constructs indicated that phosphorylation of p65 at serine 276 
mediates LPS-dependent repression of Prx I gene activation by PMA (Figure 6, paper 
I). Phosphorylation of p65 at serine 276 is a post-translational mechanism that 
controls NF-κB activity, and is essential for the interaction of this TF with the 
transcriptional coactivator p300/CREB-binding protein (Hayden and Ghosh, 2004). 
Accordingly, overexpression of p300 up-regulated Prx I promoter activity suggesting 
that p300 is involved in the NF-κB-dependent regulation of Prx I gene expression 
(Figure 7, paper I). 
Btk, a non-receptor tyrosine kinase has previously been shown to mediate LPS-
dependent toll-like receptor-4 (TLR4) signaling by modulating NF-κB activity in 
monocytic cells (Horwood et al., 2003 and Doyle et al., 2005). Therefore, the role of 
Btk for the regulation of Prx I gene expression was investigated. Treatment with the 
Btk inhibitor LFM-A13 not only attenuated LPS-dependent repression of Prx I gene 
activation by PMA, but also down-regulated this effect on phosphorylation of p65 at 
serine 276 (Figures 8 and 9, paper I). 
In conclusion, LPS-dependent inhibition of Prx I gene activation by PMA is 
regulated via a pathway that involves phosphorylation of the NF-κB subunit p65 at 
serine 276 (Figure 5). In addition, the present findings suggest cross-talk between 
signaling mechanisms that regulate Prx I gene expression by PMA and LPS in 
monocytic cells.  
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Figure 5: Signaling pathways of Prx I gene a
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Abstract
Peroxiredoxin I (Prx I) is an antioxidant enzyme with thioredoxin-dependent peroxidase activity which is involved in various cellular processes
such as regulation of cell proliferation. Here, it is shown that the proinflammatory mediator lipopolysaccharide (LPS) inhibits the induction of Prx I
expression and promoter activity by the phorbol ester 12-O-tetradecanoylphorbol- 13-acetate (TPA) in RAW264.7 monocytes, but not that of
cyclooxygenase-2. LPS-dependent repression of Prx I induction by TPAwas mediated via a newly identified κB site in the Prx I promoter, but the
“classical” NF-κB cascade was not involved in this regulatory pathway, because IκB did not affect LPS-mediated Prx I repression. By contrast,
phosphorylation of p65 at serine 276, which enhances the transcriptional activity of NF-κB, was up-regulated by TPA and was reduced by
simultaneous exposure to LPS. Functional studies with Gal4–p65 constructs revealed that serine 276 is crucial to confer LPS-dependent repression of
TPA-mediated induction of p65 transactivation. Finally, repression of TPA-dependent Prx I induction by LPS was mediated via Bruton's tyrosine
kinase as indicated by studies with the pharmacological inhibitor LFM-A13. In summary, LPS-dependent inhibition of Prx I gene activation by TPA
in monocytes is regulated via a pathway that involves phosphorylation of the NF-κB subunit p65 at serine 276.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Antioxidant; Peroxiredoxin; Gene expression; NF-κB; Oxidative stress; Monocytes; Inflammation; Signaling; Free radicals
Peroxiredoxin (Prx) I is a multifunctional protein with
thioredoxin-dependent peroxidase activity and belongs to the
Prx protein family [1–3]. Prx I was initially identified as stress-
inducible macrophage 23-kDa stress protein in mouse peritoneal
macrophages (MSP23) [4], as proliferation-associated gene
(PAG) [5] in various human cell lines, and as heme-binding
protein 23 (HBP23) [6] in rat liver. The physiological functions
of Prx I comprise cytoprotection against oxidative stress, modu-
lation of intracellular signaling cascades that apply hydrogen
peroxide as a second-messenger molecule, and regulation of cell
proliferation and differentiation [7]. Mice with a targeted
deletion of the Prx I gene have been reported to develop
hemolytic anemia with an increase in reactive oxygen species in
erythrocytes and malignancies such as sarcomas, lymphomas,
and carcinomas, suggesting that Prx I may function as a tumor
suppressor [8,9]. In contrast, it has also been demonstrated by
others that Prx I is highly expressed in a number of malignant
tumors and may promote an aggressive survival type of tumor
cells and resistance to tumor therapy [10,11]. A number of
stimuli, among them the phorbol ester 12-O-tetradecanoylphor-
bol- 13-acetate (TPA), induce Prx I gene expression at the
transcriptional level [12–15]. We have previously demonstrated
that TPA-dependent Prx I gene expression is activated in mono-
cytic cells via a protein kinase C (PKC)/Ras-dependent signaling
pathway that targets the transcription factor (TF) activator
protein-1 (AP-1) [16].
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Because chronic inflammation is a major risk factor for
cancer [17] and Prx I may be involved in the complex se-
quence of events that cause malignancy in inflammatory
disease, we asked whether the prototypical proinflammatory
mediator lipopolysaccharide (LPS), which activates toll-like
receptor-4 (TLR4) signaling in immune cells [18], would af-
fect Prx I gene expression in monocytic cells. Thus, the goal
of the present study was to investigate the molecular mech-
anisms that regulate Prx I gene expression in response to TPA
and LPS and the potential cross-talk of signaling pathways
that are activated by these two compounds in mononuclear
cells.
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Here, it is reported that exposure to LPS markedly inhibits
the TPA-dependent induction of Prx I gene expression in
monocytic cells. This repression of Prx I induction by LPS did
not involve the “classical” NF-κB signaling cascade, but was
regulated via a Bruton's tyrosine kinase (Btk)-dependent
pathway that was mediated by phosphorylation at serine 276
of NF-κB subunit p65.
Materials and methods
Materials
Dulbecco's modified Eagle medium, RPMI 1640, and MEM
were obtained from PAA Laboratories (Pasching, Germany).
Medium M199 was from Gibco (Grand Island, NY, USA), fetal
bovine serum was from Biochrom KG (Berlin, Germany),
polyvinylidene difluoride membranes were from Millipore
(Bedford, MA, USA), radioisotopes were from Amersham
Biosciences. All other chemicals were purchased from Sigma
and Roche Applied Science, unless otherwise indicated.
Cell culture
All cell lines were from the American Type Culture Collec-
tion (Manassas, VA, USA). RAW264.7 cells were grown in
Dulbecco's modified Eagle medium, U937 cells in RPMI 1640,
Chinese hamster ovary cells in MEM, and ECV304 cells in
M199. All media were supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cell
cultures were kept under air/CO2 (19/1) at 100% humidity.
Treatment of cells with TPA (0.5 μM), LPS (1 μg/ml; Escheri-
chia coli 0111:B4), or recombinant mouse tumor necrosis factor-
α (TNF-α, 25 μg/ml) was performed with serum-free medium.
The small-molecule inhibitor of Btk LFM-A13 (Calbiochem)
was added to the culture medium at the indicated concentrations
1 h before treatment with TPA and/or LPS.
Western blot analysis
After cell cultures were washed twice with 0.9%NaCl, 300 μl
of 1× Laemmli buffer (2% SDS, 10% glycerol, bromophenol
blue, 0.4 mol/L dithiothreitol, 4% protease inhibitor) was added,
and cells were scraped from culture dishes and then homo-
genized by passing through a 25-gauge needle. The homogenate
was incubated for 3 min at 95 °C and the protein content was
determined in the supernatant by the Bradford method. Total
protein (30–60 μg) was loaded onto a 12% SDS–polyacryla-
mide gel and was blotted onto polyvinylidene difluoride-
membranes by electroblotting. Membranes were blocked with
Tris-buffered saline containing 5% skim-milk or 5% bovine
serum albumin, 50 mM Tris/HCl (pH 7.6), 150 mM NaCl, and
0.1% Tween 20, for 1 h at room temperature. The primary
polyclonal rabbit antibody against rat Prx I [19] was added at
1:5000 dilution in blocking buffer and the membrane was incu-
bated for 1 h at room temperature. The primary rabbit polyclonal
antibody against cyclooxygenase (COX)-2 (Alexis Biochem-
icals; Grünberg, Germany) was used at 1:3000 and the mouse
monoclonal antibody to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (HyTest Ltd., Turku, Finland) was used at
1:1000 dilution. The primary antibodies for the detection of the
phosphorylated inhibitor of nuclear factor-κB (IκB)-α (serine
32) and phosphorylated serine 276 of p65 were from Cell
Signaling (Beverly, MA, USA) and were applied at the concen-
trations recommended by the manufacturer. The secondary anti-
bodies were goat anti-rabbit IgG horseradish peroxidase and
anti-mouse IgG horseradish peroxidase (DPC Biermann, Bad
Nauheim, Germany) and used at 1:20,000 and 1:100,000, re-
spectively. A commercial detection system (Lumi-Light; Roche
Applied Science) was used for the detection of chemilumines-
cence signals according to the manufacturer's instructions. The
obtained chemiluminescent autoradiographic signals were
scanned by videodensitometry and quantitated with ImageQuant
software [20].
Plasmid constructs
The luciferase reporter gene constructs pPrx-1750, pPrx-
1209, pPrx-897, pPrx-558, and pPrx-558mutAB have pre-
viously been described [16]. The reporter gene construct pPrx-
1750-κBmut, which contains targeted mutations of the Prx-κB
site (−1024 to−1015) within the proximal Prx I promoter region
(Fig. 3A), was generated with the QuickChange XL-site-
directed mutagenesis kit (Stratagene) according to the manufac-
turer's instructions with the plasmid pPrx-1750 as a template.
Reporter gene plasmid NF-κB with three copies of the NF-κB
consensus sequence was obtained from Dr. Lienhard Schmitz
(University of Giessen, Giessen, Germany), plasmid pAP-1 with
six -AP-1 repeats in front of a minimal fos promoter was from
Dr. Craig Hauser (Burnham Institute, La Jolla, CA, USA) [21],
plasmid pCOX-724 with the −724 bp proximal promoter of the
mouse COX-2 gene was from Dr. Harvey Herschman (UCLA,
Los Angeles, CA, USA) [22], and plasmid pTNF-585 was from
Fig. 1. LPS inhibits TPA-dependent Prx I gene expression in monocytic cells. (A) Cell cultures were treated with TPA (0.5 μM), LPS (1 μg/ml), TPA plus LPS (T + L),
or control medium (Ctrl) for 18 h, as indicated. Total protein (30 μg) was subjected to Western blot analysis and probed sequentially with antibodies against Prx I,
COX-2, and GAPDH. A representative autoradiogram is shown and autoradiographic signals of three independent experiments were obtained by chemiluminescence
and scanned by videodensitometry. Values±SE represent the fold- induction of Prx I or COX-2 normalized to GAPDH from these three experiments. Student's t test
for paired values: significant differences, treatment versus control, ⁎p≤0.05; TPA + LPS versus TPA, ⁎⁎p≤0.05. (B) RAW264.7 cells were transiently transfected
with reporter gene construct pPrx-1750, pCOX-724, or pTNF-585 or (C) pAP-1, pPrx-558, or pPrx-558mutAB. Transfected cells were treated with TPA (0.5 μM), LPS
(1 μg/ml), TPA plus LPS, or control medium for 18 h, as indicated, after which cell extracts were assayed for luciferase activity. The -fold induction relative to the
control was determined. Values are means±SE from at least three independent experiments with duplicates of each point. Student's t test for paired values: significant
differences, ⁎TPA versus control, ⁎⁎TPA + LPS versus TPA, ⁎⁎⁎LPS versus control, p≤0.05. (D) Cells were transfected with pPrx-1750 and pNF-κB. After
transfection cells were treated with recombinant mouse TNF-α (25 μg/ml), LPS, and TPA for another 18 h, as indicated. Luciferase analysis was done in the same way
as described for (B). Student's t test for paired values: significant differences, ⁎treatment versus control, ⁎⁎TPA + LPS versus TPA, p≤0.05.
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Dr. Gordon Duff (University of Sheffield, Sheffield, UK) [23].
The expression vector with the constitutive active Ras has been
described previously [16,24]. The expression vector with the
dominant negative mutant of IκB was from Dr. Richard Gaynor
(Southwestern Medical Center, Houston, TX, USA). Plasmids
pGal4-p65, pGal4-p65 S276C, and pGal4-p65 S536A, which
contain the transactivation domain of TF p65/RelA fused to the
DNA-binding domain of yeast Gal4, were gifts from Dr. Guy
Haegeman (University of Gent, Gent, Belgium) [25]. Empty
control vector pFC2-dbd and the luciferase reporter vector pFR-
luc with five copies of the yeast Gal4 binding element were from
Stratagene. Expression plasmid pRSV-NF-κB, which expresses
RelA/p65, was fromDr. Dieter Schmoll (Sanofi Aventis Pharma;
Frankfurt/Main, Germany) [26].
Transfection and luciferase assay
After growth for 24 h, transfection of plasmid DNA into
RAW264.7 cells was performed by the liposome method using
FuGENE (Roche Applied Science) [16]. Unless otherwise
stated cells were transfected with 1 μg of luciferase reporter
plasmid and in cotransfection experiments with 0.1 to 1.5 μg
of the indicated expression vectors along with 0.25 μg Renilla
luciferase expression vector (pRL-SV40) to control for trans-
fection efficiency [20]. Cells were lysed with 1× luciferase lysis
reagent (Promega) and luciferase activitywas determinedwith the
commercial Dual Luciferase Reporter Assay System (Promega)
according to the manufacturer's instructions. Cells were either
harvested 24 h after transfection or cultured for another 18 h under
the indicated conditions. Relative light units of firefly luciferase
activity were normalized with Renilla luciferase activity, as
described previously [20].
Preparation of nuclear extracts (NE) and electrophoretic
mobility shift assay (EMSA)
Nuclear extracts were prepared as described [16]. The
sequences of the oligonucleotides used for the EMSA are as
follows: Prx-κB, 5′-CGAGACCCTTGGGACTCTCTGGGT-
CTGGTT-3′; Prx-κB mutant (Prx-κBmut), 5′-CGAGACCCTT-
GCTACAGTCTGGGTCTGGTT-3′; and NF-κB consensus
oligonucleotide, 5′-AGTTGAGGGGACTTTCCCAGGC-3′,
along with the respective oligonucleotides of the non-coding
strand. Equal amounts of complementary oligonucleotides were
annealed and labeled by 5′-end labeling with [γ-32P]-dATP and
T4 polynucleotide kinase and were purified with a nucleotide
removal kit. Binding reactions were carried out in a total volume
of 20 μl containing 50 mMKCl, 1 mMMgCl2, 1 mMEDTA, 5%
glycerol, 10 μg of nuclear extract, 250 ng poly(dI–dC), and 5mM
dithioerythritol. For competition analyses a 100-foldmolar excess
of unlabeled oligonucleotides was added. After preincubation for
5 min at room temperature, 1 μl of the labeled probe (104 cpm)
was added and the incubation was continued for an additional
10 min. For supershift analysis an antibody directed against the
NF-κB p65 subunit (sc-8008; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) and rabbit preimmune serum as a control were
added to the EMSA reaction, which was incubated at 4 °C for 2 h.
Electrophoresis was performed with a 4.5% non-denaturing
polyacrylamide gel in TBE buffer (89 mM Tris, 89 mM boric
acid, 5 mM EDTA) at 200 V. After electrophoresis the gels were
dried and exposed to X-ray films.
Table 1
Regulation of Prx I promoter activity by TPA and LPS in chinese hamster ovary
and human endothelial cells (ECV 304)
Treatment -fold induction of luciferase activity
CHO ECV304
Ctrl 1.0 1.0
TPA 1.5±0.3 3.5±0.3
LPS 1.5±0.1 1.0±0.1
TPA+ LPS 2.0±0.2 4.0±0.2
CHO and ECV304 cells were transfected with reporter gene construct pPrx-
1750. After transfection cells were treated with TPA (0.5 μM), LPS (1 μg/ml),
TPA plus LPS or control medium, as indicated. After 18 h cell extracts were
assayed for luciferase activity and the - fold induction relative to the control was
determined. Values are means±S.E from of at least three independent
experiments with duplicates of each point. CHO, chinese hamster ovary.
Fig. 2. Inhibitory effect of LPS on Ras-dependent induction of Prx I promoter activity. RAW264.7 cells were cotransfected with pPrx-1750 and an expression vector
with a constitutively active mutant of Ras (Ras ca) or an empty control vector (EV). After transfection cells were treated with LPS (1 μg/ml) for another 18 h. Cell
extracts were assayed for luciferase activity and the -fold induction relative to the control was determined. Values are means±SE from at least three independent
experiments with duplicates of each point. Student's t test for paired values: significant differences, ⁎control medium+ Ras ca versus control medium + EV, ⁎⁎LPS +
Ras ca versus control medium + Ras ca; p≤0.05.
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Results
LPS inhibits the TPA-dependent induction of Prx I gene expression
We examined the effects of the phorbol ester TPA and the
proinflammatory mediator LPS on endogenous Prx I protein
expression in the monocytic cell line RAW264.7. In line with a
previous report [16] we found that TPA induced Prx I
expression, whereas LPS caused only a minor enhancement
of Prx I expression. Interestingly, simultaneous treatment of
cells with TPA and LPS reduced TPA-dependent induction of
Prx I expression (Fig. 1A). A similar Prx I gene expression
pattern was also found in the human monocyte cell line U937
(Fig. 1A). To test the specificity of the inhibitory LPS effect on
Prx I gene regulation, we also examined the gene expression of
COX-2, which is known to be induced by these two stimuli
[27]. Treatment of cells with TPA and LPS, either alone or in
combination, up-regulated COX-2 expression (Fig. 1A), indi-
cating that the inhibitory action of LPS on TPA-dependent
induction is specific for Prx I.
To investigate whether LPS-mediated inhibition of TPA-
dependent induction of Prx I gene expression occurs on the
transcriptional level, we determined the regulation of Prx I
promoter activity by these two compounds in transiently trans-
fected RAW264.7 cells. Similar to the regulatory pattern of
endogenous Prx I gene expression in RAW264.7 cells, TPA
induced luciferase activity of a reporter gene construct with the
proximal 1750 bp of the rat Prx I gene promoter (pPrx-1750)
(Fig. 1B). LPS caused only a minor up-regulation of Prx I
promoter activity and reduced the TPA-dependent induction of
Prx I promoter activity when added in combination with TPA
(Fig. 1B). To examine the specificity of this LPS-mediated
repression of Prx I, we studied the effects of TPA and LPS on
the activity of the COX-2 (pCOX-724) and TNF-α (pTNF-585)
gene promoters, both of which are known to be prominently up-
regulated by these two compounds [27,28]. In contrast to Prx I,
combined treatment with TPA plus LPS did not significantly
reduce COX-2 and TNF-α promoter activities (Fig. 1B).
Because TPA-dependent Prx I gene induction has previously
been shown to be mediated via AP-1 [16], we also examined
the regulation of a reporter gene construct with six copies of the
AP-1 consensus sequence [21]. Simultaneous treatment with
TPA plus LPS caused an additive induction of AP-1 reporter
gene activity (Fig. 1C). To further elucidate the weak induction
of Prx I promoter activity by LPS, we also determined the
regulation of a reporter gene construct with two functional AP-1
sites of the proximal Prx I promoter region (Fig. 1C; pPrx-558).
Exposure to LPS up-regulated reporter gene activity of this
construct to an extent similar to that observed for pPrx-1750
(Fig. 1B). In contrast, this up-regulation was not observed for a
construct in which these two AP-1 sites were inactivated by site-
directed mutagenesis (pPrx-558mutAB; Fig. 1C).
Because LPS and TNF-α activate overlapping signaling
cascades in mononuclear cells [18,29,30], we also determined
the effects of TNF-α on TPA-dependent Prx I promoter
induction. In contrast to LPS, exposure to TNF-α did not affect
induction of Prx I promoter activity by TPA (Fig. 1D).
Regulation of a reporter gene construct with three copies of
the κB enhancer consensus sequence by these compounds is
shown as a control (Fig. 1D). Finally, a different regulation of
Prx I promoter activity was observed in transfected Chinese
hamster ovary cells and the endothelial cell line ECV304.
Although in both cell lines Prx I promoter activity was induced
by TPA and LPS (Table 1), the TPA-dependent induction of Prx
I was not inhibited by simultaneous treatment with LPS.
Taken together, the data indicate that LPS inhibits the TPA-
dependent induction of Prx I gene expression in a cell-specific
manner in monocytes.
Fig. 3. Role of the Prx-κB site for regulation of Prx I promoter activity.
(A) Localization of the Prx-κB site within the Prx I promoter and DNA sequence
comparisonwith the κB enhancer consensus sequence (box).Mutated baseswithin
the pPrx-1750-κBmut construct are underlined. (B) The indicated Prx I reporter
gene constructs were transfected into RAW264.7 cells. Cells were treatedwith TPA
(0.5 μM), LPS (1 μg/ml), TPA plus LPS, or control medium for 18 h and luciferase
activity was determined as described for Fig. 1. Values are means±SE from at least
three independent experiments with duplicates of each point. Student's t test for
paired values: significant differences, ⁎TPAversus control, ⁎⁎pPrx-1209 + TPA +
LPS versus pPrx-1209 + TPA, p≤0.05. (C) RAW264.7 cells were cotransfected
with the constructs pPrx-1750, pPrx-1750-κBmut, or pTNF-585 and an expression
vector for the NF-κB subunit p65 or empty control vector (EV), as indicated. 24 h
after transfection cells were treated for another 18 h with TPA or control medium.
Luciferase analysis was done in the same way as described for (B). Student's t test
for paired values: significant differences, ⁎pPrx-1750 + p65 versus pPrx-1750 +
EV, pTNF-585 + p65 versus pTNF-585+ EV, ⁎⁎pPrx-1750-κBmut + p65 versus
pPrx-1750 + p65, p ≤ 0.05.
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LPS inhibits Ras-dependent activation of Prx I transcription
The small GTP-binding protein Ras has previously been
shown to be involved in TPA-dependent induction of Prx I gene
expression [16]. To evaluate the role of Ras in the LPS-
dependent inhibition of Prx I gene induction by TPA, we
examined the effect of LPS on the regulation of Prx I promoter
activity by a cotransfected expression vector with a constitu-
tively activated mutant of Ras. Treatment with LPS markedly
decreased the Ras-dependent induction of Prx I promoter
activity (Fig. 2). By contrast, LPS had an additive effect on Ras-
dependent induction of reporter gene constructs with either the
COX-2 promoter region or six copies of the AP-1 consensus site
(Fig. 2, for a comparison see also Fig. 1).
The data indicate that LPS-dependent inhibition of TPA-
dependent Prx I promoter induction occurs downstream of Ras.
Identification of a functional κB site in the proximal Prx I gene
promoter region
A common intracellular target of TPA- and LPS-dependent
signaling is the NF-κB pathway, which is a major regulator of
numerous genes in mononuclear cells. NF-κB is able to bind
promoter and enhancer regions of various genes that contain κB
sites [31,32]. A potential κB element of the Prx I promoter was
identified between positions −1024 and −1015 bp relative to
the transcription initiation site, which matches the κB consensus
sequence in 9 of 10 bp (Fig. 3A). To assess the regulatory
capacity of this putative κB enhancer element, we generated
two Prx I reporter gene constructs, either with (pPrx-1209) or
without the Prx-κB site (pPrx-897). Transfection of these
constructs into RAW264.7 cells revealed that up-regulation of
Prx I promoter activity in response to TPA was reduced after
deletion of the Prx-κB site (Fig. 3B). Importantly, the LPS-
dependent inhibition of Prx I induction by TPA was not
observed for pPrx-897 (Fig. 3B). In the following, we deter-
mined the functionality of the Prx-κB site by mutation studies.
When cotransfected with an expression vector for the NF-κB
subunit p65, which is also termed RelA, targeted mutation of
the Prx-κB site (pPrx-1750-κBmut) reduced the extent of
reporter gene induction compared to the wild-type construct
(Fig. 3C). The magnitude of TPA-dependent induction was
significantly lower for the Prx I reporter gene construct with the
mutated κB site (data not shown). This seemed to be specific,
because p65-dependent regulation of a TNF-α promoter
construct (pTNF-585) with functional κB- sites was similar to
that of pPrx-1750 when used as a control (Fig. 3C, bottom).
Taken together, the data suggest that the Prx-κB site is
involved in LPS-dependent inhibition of Prx I gene transcrip-
tion and serves as a functional target for the NF-κB subunit p65.
The Prx-κB site is a nuclear target of p65
DNA–protein interactions in NE from RAW264.7 cells were
determined for an oligonucleotide with the Prx-κB site by
Fig. 5. Role of IκB in the regulation of Prx I promoter activity. (A) RAW264.7
cells were treated with TPA (0.5 μM), LPS (1 μg/ml), TPA plus LPS, or control
medium for 3 h, as indicated. Total protein (60 μg) was subjected toWestern blot
analysis and probed sequentially with antibodies against phosphorylated IκBα
(serine 32) or total IκBα. (B) Cells were cotransfected with pPrx-1750 and an
expression vector for dominant negative IκB (IκB dn) or empty control vector
(EV), as indicated. After transfection cells were treated with TPA plus LPS for
another 18 h. Cell extracts were assayed for luciferase activity and the -fold
induction relative to the control was determined. Values are means±SE from at
least three independent experiments with duplicates of each point. Student's t test
for paired values: significant difference, TPA + LPS versus control, ⁎p≤0.05.
Fig. 4. Binding of nuclear protein to the Prx-κB site. (A) EMSA. A 32P-labeled
oligonucleotide with the Prx-κB element was incubated with 20 μg of NE from
control (Ctrl) or TPA- (0.5 μM), LPS- (1 μg/ml), or TPA plus LPS- (T + L)-
treated cells or without NE as a free probe, as indicated. (B) For supershift
analysis NE from TPA-treated cells was preincubated with 3 and 2 μl of antibody
against the NF-κB p65 subunit for 1 h at 4 °C before the radiolabeled Prx-κB
probe was added (lanes 2 and 3). For competition analyses the radiolabeled Prx-
κB oligonucleotide was preincubated with NE from TPA-treated cells along with
a 50-fold molar excess of unlabeled NF-κB consensus or Prx-κB site
oligonucleotides, as indicated (lanes 4 and 5). DNA–protein complexes were
separated by electrophoresis on a 4.5% polyacrylamide gel.
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EMSA. NE from cells which were treated with TPA alone
showed a markedly stronger DNA-binding activity to the Prx-
κB oligonucleotide than NE from control cells (Fig. 4A). By
contrast, NE from cells that were treated with LPS alone did not
show inducible DNA-binding to the Prx-κB site and, unex-
pectedly, NE from cells that were treated with a combination of
TPA plus LPS exhibited a DNA–protein band similar to that
observed for TPA alone (Fig. 4A). Incubation of the binding
reaction with an antibody directed against the NF-κB subunit
p65 reduced formation of the DNA–protein complex (Fig. 4B),
Fig. 6. Phosphorylation of p65 at serine 276 is critical for LPS-mediated inhibition of TPA-dependent induction in RAW264.7 cells. (A) RAW264.7 cells were treated
with TPA (0.5 μM), LPS (1 μg/ml), TPA plus LPS, or control medium for the times indicated. Total protein (60 μg) was subjected to Western blot analysis and probed
sequentially with antibodies against phosphorylated serine 276 of p65 and GAPDH. Similar results were obtained in three independent experiments and a representative
autoradiogram is shown. The autoradiographic signals after 180 min were quantitated by videodensitometry. Values±SE represent the fold- induction of phospho p65-
Ser276 normalized to GAPDH from three independent experiments. Student's t test for paired values: significant differences, ⁎TPAversus control, ⁎⁎TPA + LPS versus
TPA, p≤0.05. (B) Cells were cotransfected with reporter gene constructs pFR-luc and pFC2-dbd, pGal4-p65, or the mutant pGal4-p65 S276C or pGal4-p65 S536A, as
indicated. After transfection the cells were treated with TPA, LPS, or TPA plus LPS for another 18 h. Cell extracts were assayed for luciferase activity and the -fold
induction relative to the control was determined. Values are means±SE from three independent experiments with duplicates of each point. Student's t test for paired
values: significant differences, ⁎TPA versus control, ⁎⁎TPA + LPS versus TPA, p≤0.05.
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suggesting the presence of p65. In competition EMSA studies
the intensity of a DNA–protein complex which was formed with
the Prx-κB oligonucleotide was abolished by an excess of
unlabeled oligonucleotides with either the Prx-κB site or the NF-
κB enhancer consensus sequence (Fig. 4B).
Thus, the data suggest that the Prx-κB site is a specific
nuclear binding site for the NF-κB subunit p65.
IκB is not involved in LPS-mediated inhibition of
TPA-dependent Prx I gene activation
Nuclear translocation of p65 occurs after release from the
cytosolic inhibitor protein IκB, which is regulated via phos-
phorylation of specific regulatory serines in the N-terminal IκB
region. This phosphorylation serves as a signal for subsequent
proteasomal degradation of IκB and is referred to as the
“canonical” or “classical”NF-κBpathway [31,32]. To investigate
the regulatory potential of this pathway in RAW264.7 cells, we
determined the phosphorylation of serine 32 of IκBα with a
phosphospecific antibody. Phosphorylation of serine 32 was
markedly up-regulated in response to TPA or LPS alone and
simultaneous incubation with TPA plus LPS had a similar effect
on the level of IκB phosphorylation compared to that observed
for treatment with either compound alone (Fig. 5A). To determine
the functional role of IκB on Prx I promoter regulation by TPA
and LPS, we also applied an expression vector with a dominant
negative mutant of IκB for cotransfection studies. Overexpres-
sion of this dominant negative IκB did not have a major effect on
LPS-mediated repression of TPA-dependent Prx I promoter
induction (Fig. 5B), but reduced LPS-dependent induction of the
control reporter gene plasmid pNF-κB (data not shown).
Collectively, the data on IκB-mediated regulation of Prx
promoter activity along with that of the EMSA studies (Fig. 4)
suggest that the LPS-mediated inhibition of Prx I gene induction
by TPA is not mediated via the classical NF-κB pathway.
LPS inhibits TPA-dependent phosphorylation of p65 at serine
276 and activity of a Gal4–p65 fusion protein
The NF-κB subunit p65 is a principal target for regulatory
phosphorylation by stimulus-coupled kinase activity. Rapid and
reversible phosphorylation of p65 at specific regulatory sites
provides an important mechanism to modulate the transactiva-
tion capacity of NF-κB [31,33]. Because serine 276 plays a
major regulatory role in gene activation by p65 [32], we
examined the phosphorylation of serine 276 during treatment
with TPA and LPS for up to 3 h in RAW264.7 cells with a
phosphospecific antibody. Phosphorylation of serine 276 was
visible as early as 5 min after exposure to TPA and the level of
serine 276 phosphorylation was further up-regulated in a time-
dependent manner (Fig. 6A). By contrast, treatment with LPS
alone caused only a lower increase in serine 276 phosphoryla-
tion, and simultaneous treatment with TPA plus LPS reduced
the level of serine 276 phosphorylation compared to treatment
with TPA alone (Fig. 6A).
To investigate the functional relevance of serine 276
phosphorylation by TPA and LPS on p65 transactivation
capacity, we also determined the regulation of the activity of a
pGal4-p65 construct, in which p65 is fused to the DNA-binding
domain of yeast Gal4. As monitored by luciferase activity of a
cotransfected Gal4 reporter gene construct (pFR-luc), TPA
significantly increased p65 transactivation. By contrast, LPS
alone caused only a lower induction and the combination of
TPA plus LPS led to a significant repression of luciferase
activity compared with TPA alone (Fig. 6B). We also evaluated
the regulation of a mutated Gal4–p65 construct, in which serine
276 of p65 was replaced by cysteine (Gal4-p65 S276C).
Although basal luciferase activity of pGal4-p65 S276C was
lower in comparison to that of wild-type pGal4-p65, treat-
ment with TPA induced luciferase activity of this construct.
Remarkably, and in contrast to wild-type pGal4-p65, simulta-
neous exposure of cells transfected with pGal4-p65 S276C to
TPA plus LPS led to enhanced levels of luciferase activity,
which were comparable to levels that were observed upon
treatment with TPA alone (Fig. 6B). A similar regulatory pattern
was observed for a pGal4-p65 mutant construct, in which serine
276 was replaced by alanine (data not shown). For comparison
we examined the TPA- and LPS-dependent regulatory pattern of
a Gal4–p65 fusion plasmid, in which serine 536 of the p65
transactivation domain was replaced by alanine. Similar to the
pGal4-p65 S276C mutant, the basal activity of this construct
was lower than that of wild-type pGal4-p65. Repression by LPS
of TPA-dependent induction, however, was not lost with this
construct, which is in contrast to the regulatory pattern observed
for pGal4-p65 S276C mutant and indicates specificity for the
effects observed with the latter construct.
Taken together, the data indicate that phosphorylation at
serine 276 of p65 and transactivation of pGal4-p65 are induced
by TPA and inhibited by simultaneous exposure to LPS.
Fig. 7. Effect of overexpressed p300 on the regulation of Prx I promoter activity.
RAW264.7 cells were cotransfected with pPrx-1750 and an expression vector
for p300 or empty expression vector (EV). After transfection incubation of cells
was continued with or without TPA (0.5 μM) for another 18 h. Cell extracts were
assayed for luciferase activity and the -fold induction relative to the control was
determined. Values are means±SE from at least three independent experiments
with duplicates of each point. Student's t test for paired values: significant
differences, ⁎TPA + EV versus control medium + EV and TPA + p300 versus
control medium + p300, ⁎⁎TPA + p300 versus TPA + EV, p≤0.05.
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Overexpression of p300 increases TPA-dependent Prx I
promoter activity
Phosphorylation of serine 276 causes a conformational
change in p65 that allows efficient recruitment of the co-
activator p300/CREB-binding protein and increases gene
transcription [31,32]. To explore the possibility that serine
276-dependent phosphorylation is involved in the regula-
tion of Prx I gene expression, we determined the effect of a
cotransfected expression vector for p300 on Prx I promoter
activity. Overexpressed p300 enhanced the basal and the
TPA-dependent induction of Prx I promoter activity (Fig. 7),
suggesting that p300 is involved in the regulation of Prx I
gene expression.
Inhibition of BrutonTs tyrosine kinase blocks the repressive effect
of LPS on TPA-dependent induction of p65 transactivation and
phosphorylation of p65 at serine 276
Btk, which is a member of the Tec family of non-receptor
tyrosine kinases, is involved in LPS signaling via TLR4 in
mononuclear cells [34–36]. To investigate the potential role of
Btk for Prx I gene expression, we determined the effect of the
pharmacological Btk inhibitor LFM-A13 on the regulation of
pGal4-p65 activity by TPA and LPS. Pretreatment with LFM-
A13 markedly reduced the LPS-dependent repression of TPA-
dependent transactivation of pGal4-p65 (Fig. 8A). Moreover,
the effect of LFM-A13 was evaluated for Prx I promoter regu-
lation by these compounds. Similar to the regulation of pGal4-
p65 transactivity, exposure to LFM-A13 prevented the
inhibitory effect of LPS on TPA-dependent induction of Prx
promoter activity (Fig. 8B). To explore the possibility that the
functional regulation of p65 transactivation and Prx I promoter
activity in RAW264.7 cells would be mediated via Btk, we also
determined the levels of p65 phosphorylation at serine 276 by
TPA and LPS in the presence or absence of LFM-A13.
Importantly, LPS-mediated inhibition of p65 phosphorylation
by TPA at serine 276 was blocked by pretreatment with LFM-
A13 (Fig. 9).
Fig. 9. LFM-A13 blocks the inhibitory effect of LPS on TPA-dependent induction
of p65 phosphorylation at serine 276. (A) RAW264.7 cells were treated with TPA
(0.5 μM) plus LPS (1 μg/ml) in the presence or absence of LFM-A13 (LFM;
100 μM) for 3 h, as indicated. Total protein (60 μg) was subjected to Western blot
analysis and probed sequentiallywith antibodies against phosphorylated serine 276
of p65 and GAPDH. Similar results were obtained in three independent
experiments and a representative autoradiogram is shown. (B) The autoradiogra-
phic signals of (A) were quantitated by videodensitometry. Values±SE represent
the -fold induction of phospho p65-Ser276 normalized to GAPDH from three
independent experiments. Student's t test for paired values: significant differences,
⁎treatment versus control, ⁎⁎TPA + LPS versus TPA, p≤0.05.
Fig. 8. Inhibition of Btk by LFM-A13 attenuates repression of TPA-dependent
induction of the Prx I promoter by LPS. Cells were transfected (A) with pFR-luc
and pFC2-dbd or pGal4-p65 and (B) with pPrx-1750. After transfection cells
were pretreated with LFM-A13 (LFM; 100 μM) for 1 h, after which cell culture
was continued for another 18 h with TPA (0.5 μM), LPS (1 μg/ml), or TPA plus
LPS, as indicated. Cell extracts were assayed for luciferase activity and the -fold
induction relative to the control was determined. Values are means±SE from at
least three independent experiments with duplicates of each point. Student's t
test for paired values: significant differences, ⁎TPA versus control, ⁎⁎TPA +
LPS versus TPA, p≤0.05.
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The data indicate that the non-receptor tyrosine kinase Btk is
involved in LPS-mediated inhibition of TPA-dependent induc-
tion of Prx I gene expression via specific regulation of p65
phosphorylation at serine 276.
Discussion
The antioxidant Prx I is a thioredoxin-dependent peroxidase
which belongs to the Prx family. Members of this protein family
have been identified in a variety of organisms ranging from
bacteria to mammals [1–3,7]. Gene expression of Prx I has
previously been shown to be induced by oxidative stress stimuli
[7]. The major findings of the present study are that the
prototypical proinflammatory mediator LPS inhibits the tran-
scriptional induction of Prx I gene expression by the tumor
promoter TPA in monocytic cells. NF-κB, which binds to a
newly identified κB site of the Prx I gene promoter, is involved
in this regulatory mechanism. Phosphorylation of the NF-κB
subunit p65 on serine 276 is up-regulated by TPA and this TPA-
dependent induction is inhibited by simultaneous exposure to
LPS. LPS-dependent repression of Prx I gene induction by TPA
is mediated via a signaling cascade downstream of Ras and
involves the non-receptor tyrosine kinase Btk.
LPS inhibits the TPA-dependent transcriptional Prx I gene
activation in monocytic cells
Prx I gene expression has previously been shown to be
induced by the tumor promoter TPA in RAW264.7 cells [16] and
by the proinflammatory stimulus LPS in primary cultured rat
liver tissue macrophages [19]. Thus, it was unexpected that the
up-regulation of the Prx I gene expression by TPAwas markedly
inhibited by simultaneous exposure to LPS in monocytic cells
(Fig. 1). LPS-mediated repression of Prx I gene induction by
TPA was cell-specific, because this inhibitory effect was not
observed in non-monocytic cells (Table 1). Moreover, such a
regulatory pattern did not apply to the regulation of the COX-2
and TNF-α genes by TPA and LPS (Fig. 1). Similar to the
negative regulation of Prx I by LPS, an inhibitory effect of LPS
has previously been reported for the constitutive and inducible
expression of the microsomal epoxide hydrolase and glutathione
S-transferase genes in rat liver [37].
Because luciferase activity of an AP-1 reporter gene
construct was induced in an additive manner by TPA plus
LPS (Fig. 1C), LPS-dependent Prx I gene repression seemed not
to be regulated via the TFAP-1. Two previously identified AP-1
sites of the Prx I promoter, however, mediated the weak
induction of Prx I by LPS (Fig. 1C). Therefore, we hypothesized
that an enhancer element(s) independent of previously char-
acterized Prx I AP-1 sites [16] would be involved in this
regulatory mechanism. Accordingly, a functional κB site of the
rat Prx I promoter was identified, which matches the κB-
enhancer consensus sequence in 9 of 10 bp (Fig. 3A). The Prx-
κB site conferred TPA-responsiveness to luciferase reporter
gene constructs and deletion of this element attenuated LPS-
mediated inhibition of TPA-dependent Prx I promoter induction
(Fig. 3). The differential regulatory pattern in response to TPA
and LPS of the Prx I, COX-2, and TNF-α promoters (Fig. 1B),
all of which contain κB sites, suggested that the configuration of
other promoter sequences may also play a role in the regulation
of these genes. The Prx- κB site served as a nuclear target for the
NF-κB subunit p65, which is synonymous with RelA (Fig. 4). It
is remarkable, however, that TPA-inducible binding of nuclear
proteins to the Prx-κB site was not changed by simultaneous
treatment with TPA plus LPS (Fig. 4). Moreover, overexpressed
dominant negative IκB had no appreciable effect on LPS-
mediated repression of Prx I promoter induction by TPA
(Fig. 5B). These findings indicate that the classical NF-κB
pathway, which governs gene expression via inducible phos-
phorylation and degradation of IκB [31,32], does not play a
major role in the LPS-mediated inhibition of Prx I gene acti-
vation by TPA. Because LPS markedly decreased TPA-induced
phosphorylation of the NF-κB subunit p65 on serine 276
(Fig. 6A), the present data suggest that direct phosphorylation
of p65 via an IκB-independent pathway mediates Prx I gene
regulation by these two compounds. In line with such a con-
clusion, TPA-induced transactivation of a wild-type Gal4–p65
fusion protein was down-regulated by simultaneous exposure to
LPS, but TPA-mediated up-regulation of a pGal4-p65 construct
with a targeted serine 276 mutation of p65 (Gal4-p65 S276C)
was not affected by LPS (Fig. 6B). The NF-κB subunit p65,
which is a principal target of inducer-specific regulatory
phosphorylation, is known to modulate the transcriptional
activity of NF-κB [31,32]. Specifically, phosphorylation of p65
on serine 276 is known to cause a conformational change to
make p65 more accessible for interaction with the transcrip-
tional coactivator p300/CREB-binding protein, which increases
transcriptional gene expression [32,38]. This mechanism may
also be involved in transcriptional Prx I gene regulation,
because basal and TPA-regulated Prx I promoter activity was
strongly enhanced by overexpressed p300 (Fig. 7).
Inhibitory effects that are brought about by modulation of the
transcriptional activity of NF-κB have previously been reported
for the regulation of other genes. Waltner-Law et al. have shown
that NF-κB represses the induction of phosphoenolpyruvate
carboxykinase gene expression by glucocorticoids and cAMP in
hepatoma cells [39]. Moreover, interleukin-1 has been shown to
inhibit the up-regulation of the α2-macroglobulin gene by
interleukin-6 via interaction of NF-κB with the TF STAT3 [40].
More recently, activation of NF-κB by TNF-α has also been
reported to decrease the insulin-mediated induction of glucose-
6-phosphatase gene expression, independent of a direct DNA
interaction with the promoter of this gene [26]. To our
knowledge the present report is the first to demonstrate gene
repression that is mediated by a stimulus-coupled inhibitory
effect on p65 phosphorylation and adds to the multiple levels of
gene regulation that are mediated via NF-κB [31–33,41].
Signaling pathways that mediate the LPS-dependent inhibition
of Prx I gene induction by TPA
Activation of PKC plays a crucial role in signaling by the
phorbol ester TPA [42]. Accordingly, Prx I gene induction by
TPA has previously been shown to be regulated via a PKC/Ras-
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mediated pathway in mononuclear cells [16]. Because LPS
strongly reduced Prx I promoter activation by Ras (Fig. 2), the
repression of Prx I gene induction by LPS is regulated via a
signaling pathway downstream of Ras. A candidate molecule
that could be involved in the inhibition of TPA-dependent Prx I
gene induction via LPS is the non-receptor tyrosine kinase Btk
[36]. This conclusion is supported by the finding that inhibition
of Btk with the small-molecule inhibitor LFM-A13 reduced not
only LPS-dependent repression of TPA-mediated induction of
Prx I promoter activity and Gal4–p65 transactivation (Fig. 8),
but also that of p65 phosphorylation at serine 276 (Fig. 9). Btk is
an important regulator of B-cell signaling [36] and has also been
shown to be involved in TLR4 signaling, which is activated by
LPS in monocytic cells [18,34]. It is entirely possible, however,
that other kinases such as the tyrosine kinase c-abl or the serine/
threonine kinase Atm, which have recently been shown to affect
Prx I gene expression [15], are involved in this regulatory
pathway. NF-κB has previously been reported to be phos-
phorylated on serine 276 of p65 via an atypical protein kinase A
[31] or mitogen- and stress-activated kinase-1 [25]. More
recently, the latter kinase has also been shown to be involved in
p65 phosphorylation via p38 MAP kinase by Borrelia
burgdorferi antigens in RAW264.7 cells [43]. Because activa-
tion of TLR4 signaling by LPS in mononuclear cells is still
incompletely understood, it is also conceivable that signaling
molecules other than kinases may be involved in LPS-
dependent gene regulation of Prx I. Potential candidates for
such a mechanism are the adaptor proteins Dok-1 and Dok-2,
which down-regulate LPS signaling in macrophages [44].
Physiological significance of Prx I gene regulation by TPA and
LPS in monocytes
The present findings suggest that different signaling pro-
grams in mononuclear cells may be integrated at the level of
Prx I gene expression. Prx I gene activation by the phorbol ester
TPA, which primarily affects cellular proliferation and differ-
entiation, is inhibited by the bacterial product LPS, which is a
prototypical proinflammatory mediator. The exact regulatory
role of Prx I with respect to carcinogenesis is contradictory. On
the one hand observations in Prx I genetically deficient mice
have suggested that this gene may be an important tumor
suppressor. On the other hand, not only has it been shown that
Prx I is highly expressed in various malignant tumors, it has also
been demonstrated that Prx I may promote an aggressive
survival type of tumor cells and resistance to tumor therapy
[10,11]. Therefore, regulation of Prx I gene expression by TPA
and LPS in mononuclear cells may have important implications
for carcinogenesis as well as chronic inflammation. It is also
remarkable that not only is Prx I gene expression regulated by
NF-κB, as demonstrated in the present report, but also that Prx
can modulate the activity of NF-κB via enzymatic degradation
of hydrogen peroxide [45]. In conclusion, further studies are
necessary to understand the regulatory mechanisms that govern
Prx I gene expression. Such studies may ultimately help to
develop novel therapeutic strategies for the treatment of cancer
and inflammation.
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3.1. HO-1 gene activation by PMA via an atypical NF-κB pathway in monocytes 
(Paper II) 
 
HO-1 gene expression was induced by PMA and LPS in monocytic cells. PMA 
and LPS, however, induced HO-1 gene expression with different time kinetics and had 
an additive effect on HO-1 gene expression when treated simultaneously (Figure 1, 
paper II). These observations suggest that distinct signaling pathways mediate HO-1 
gene activation by PMA and LPS. 
Although several earlier studies have implicated a regulatory role of NF-κB for 
the induction of HO-1 gene expression, the molecular basis of this regulation has 
remained elusive (Alam et al., 2007). The present paper identified a functional κB site 
of the rat HO-1 promoter that serves as a nuclear target for the NF-κB subunit p65. 
Functional studies and nuclear binding assays indicated that this κB site mediated the 
activation of HO-1 gene expression by PMA (Figures 2 – 4, paper II). A previously 
identified PMA-responsive element of the human HO-1 promoter (Muraosa et al., 
1993) was not functional in the context of the rat HO-1 gene promoter (Figure 2, 
paper II). These potential species-specific differences of HO-1 gene expression were 
also supported by computational comparisons of DNA-sequences from rat, mouse and 
human HO-1 gene promoters, which exhibited significant structural discrepancies. 
An IKK-independent atypical activation of NF-κB was involved in the regulation 
of HO-1 gene activation by PMA, because overexpression of IκBα, but not that of 
IKK2, attenuated PMA-dependent induction of HO-1 promoter activity (Figure 6, 
paper II). IKK-independent activation of NF-κB has previously been shown to be 
mediated via phosphorylation of IκB at tyrosine 42 in response to oxidative stress 
stimuli (Takada et al., 2003). Accordingly, treatment with PMA, a known inducer of 
ROS in monocytes (Datta et al., 2000) led to a transient phosphorylation of IκB at 
tyrosine 42 (Figure 6C, paper II). These weaker phosphorylation levels, however, do 
not correlate with the strong induction of HO-1 gene expression by PMA suggesting 
that IκB phosphorylation at tyrosine 42 does not play a major role for this induction. In 
addition, studies with the pharmacological inhibitors demonstrated that p38 MAPK 
and CK2 are involved in the regulation of PMA-dependent induction of HO-1 gene 
expression (Figures 8 – 10, paper II).  
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Therefore, it can be concluded that the PMA-dependent induction of HO-1 gene is 
regulated via an atypical NF-κB pathway that involves phosphorylation of IκB at the 
C-terminal domain in a p38 and CK2 dependent manner (Figure 6). A similar signaling 
cascade has previously been demonstrated for NF-κB activation by UV-light in HeLa 
cells (Kato et al., 2003). 
 
 
 
 
 
 
 
 
 
 
Figure 6: Signaling pathways of HO-1 gene activation by PMA 
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An Atypical NF-B-Regulated Pathway Mediates Phorbol
Ester-Dependent Heme Oxygenase-1 Gene Activation
in Monocytes1
Srivatsava Naidu,* Nastiti Wijayanti,* Sentot Santoso,* Thomas Kietzmann,†
and Stephan Immenschuh2*
Heme oxygenase (HO)-1 catalyzes the rate-limiting step of heme degradation and plays an important anti-inflammatory role via
its enzymatic products carbon monoxide and biliverdin. In this study it is reported that the HO-1 gene is transcriptionally induced
by the phorbol ester PMA in cell cultures of monocytic cells with a regulatory pattern that is different from that of LPS-dependent
HO-1 induction in these cells. Activation of HO-1 by PMA was mediated via a newly identified B element of the proximal rat
HO-1 gene promoter region (284 to 275). This HO-B element was a nuclear target for the NF-B subunit p65/RelA as
determined by nuclear binding assays and transfection experiments with luciferase reporter gene constructs in RAW264.7 mono-
cytes. Moreover, PMA-dependent induction of endogenous HO-1 gene expression and promoter activity was abrogated in em-
bryonic fibroblasts from p65/ mice. PMA-dependent HO-1 gene activation was reduced by an overexpressed dominant negative
mutant of IB, but not by dominant negative IB kinase-2, suggesting that the classical NF-B pathway was not involved in this
regulation. The antioxidant N-acetylcysteine and inhibitors of p38 MAPK or serine/threonine kinase CK2 blocked PMA-depen-
dent HO-1 gene activation. Finally, it is demonstrated by luciferase assays with a Gal4-CHOP fusion protein that the activation
of p38 MAPK by PMA was independent of CK2. Taken together, induction of HO-1 gene expression by PMA is regulated via an
IB kinase-independent, atypical NF-B pathway that is mediated via the activation of p38 MAPK and CK2. The Journal of
Immunology, 2008, 181: 4113–4123.
H eme oxygenase (HO)3-1 is the first and the rate-limitingenzyme of heme degradation (1). The catalytic cleavageof the prooxidant heme by HO produces iron, biliverdin,
and carbon monoxide (2). Biliverdin is converted into the potent
antioxidant bilirubin (3) via biliverdin reductase (4), and HO-de-
rived carbon monoxide plays an important physiological role as a
signaling gas (5, 6). HO-1 is highly inducible by a variety of ox-
idative stress stimuli and has been known for many years to pro-
vide antioxidant cellular protection (6). More recently, HO-1
knockout mice and a human case of genetic HO-1 deficiency have
been shown to exhibit phenotypical alterations of chronic inflam-
mation (7, 8). Furthermore, HO-1/ mice were highly susceptible
to the toxicity of the proinflammatory mediator LPS (7, 9), and
induction of HO-1 expression, either by gene transfer or by phar-
macological stimulation, has emerged to be of potential therapeutic
use for the treatment of inflammatory diseases in animal models
(10–15).
HO-1 is regulated primarily at the level of transcription (6, 16).
An array of cis-acting regulatory elements (RE), which are tar-
geted by transcription factors (TF) such as NF-E2-related factor 2
(Nrf2), AP-1, or USF-2, have been identified in the promoter re-
gions of avian and mammalian HO-1 genes and are involved in
HO-1 regulation (6, 17). Although the TF NF-B, which provides
cytoprotection against oxidative stress (18), has been shown to be
activated by various stimuli that are also known to up-regulate
HO-1 gene expression such as curcumin (19), LPS (20), or dietary
polyphenols (21), the regulatory role of NF-B for HO-1 gene
regulation is discussed controversially (17, 22). Moreover, a func-
tional B site of the HO-1 promoter, which is the direct target of
this TF, has not been identified to date. Thus, the goal of the
present study was to investigate the regulation of HO-1 by the
phorbol ester PMA, which is a prototypical activator of NF-B in
monocytic cells and a potent inducer of protein kinase C (PKC)
(23).
In this article it is reported that PMA induces HO-1 gene ex-
pression in monocytes. This up-regulation is mediated via a newly
identified B element of the rat HO-1 proximal promoter that is a
target of the NF-B subunit p65/RelA. An atypical IB kinase
(IKK)-independent NF-B pathway, which requires the activation
of p38 MAPK and CK2, is involved in PMA-dependent induction
of HO-1 gene expression in monocytes.
Materials and Methods
Materials
DMEM, RPMI 1640, and MEM were obtained from PAA Laboratories,
FBS was from Biochrom, Ficoll-Paque was from Pharmacia, CD14
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immunomagnetic microbeads were from Miltenyi Biotec, and polyvinyli-
dene difluoride membranes were from Millipore. All other chemicals were
purchased from Sigma-Aldrich and Roche Applied Science unless other-
wise indicated.
Cell isolation and culture
Liver tissue macrophages (LTM), peritoneal macrophages (24), rat hepa-
tocytes (25) and human PBMC were isolated and cell culture was main-
tained in culture as described previously (26). RAW264.7 cells were from
American Type Culture Collection, mouse embryonic fibroblasts (MEF)
from p65/ mice were from Dr. H. Nakano (Department of Immunology,
Jutendo University School of Medicine, Tokyo, Japan) (27) and were
grown in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and
100 g/ml streptomycin. All cell cultures were kept under air/CO2 (19:1)
at 100% humidity. Treatment of cells with PMA (0.5 M) and LPS (Esch-
erichia coli 0111:B4; 1 g/ml) was performed with serum-free medium.
Specific inhibitors of CK2, apigenin, 5,6-dichloro-1--D-ribofuranosylben-
zimidazole (RFBD) (Calbiochem), p38 MAPK inhibitor SB202190 (Cal-
biochem), IKK2 inhibitor SC-514 (Calbiochem), and N-acetylcysteine
(NAC) were added to the culture medium 30 min to 1 h before treatment
with PMA, as indicated.
RNA isolation, Northern blot analysis, and hybridization
Total RNA isolation and Northern blot analysis were essentially per-
formed as described previously and, as a probe for hybridization, the
cDNA of rat HO-1 and a 28S ribosomal RNA oligonucleotide was
applied (28).
Western blot analysis
Cells were washed with 0.9% NaCl and thereafter lysis was performed
as described (29). The lysate was centrifuged for 5 min at 13,000  g
at 4°C and the protein concentration in the supernatant was determined
by the BCA (bicinchoninic acid) protein assay kit (Pierce). Fifty mi-
crograms of total protein was separated on a 12% SDS-polyacrylamide
gel and electroblotted onto polyvinylidene difluoride membranes. Mem-
branes were blocked with Tris-buffered saline containing 5% skim milk
or 5% BSA, 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, and 0.1% Tween
20 for 1 h at room temperature. The primary Abs against HO-1 (Stress-
gen), and GAPDH (Hytest) were used at 1/1000 dilutions. The primary
Abs for the detection of phosphorylated IB serine 32 (Cell Signaling)
and tyrosine 42 (ECM Biosciences) were applied at the concentrations
recommended by the manufacturers. Secondary Abs were goat anti-
rabbit IgG HRP and anti-mouse IgG HRP (DPC Biermann) and were
used at 1/20,000 and 1/100,000, respectively. The ECL chemilumines-
cent detection system (Amersham Biosciences) was used for detection
according to the manufacturer’s instructions.
Plasmid constructs
The luciferase reporter gene constructs pHO-1338, pHO-754, and pHO-
347 have been described previously (28), pTNF-585 was from Dr. G.
Duff (University of Sheffield, Sheffield, U.K.), and pNF-B was from
Dr. L. Schmitz (University of Giessen, Giessen, Germany). The expres-
sion vector for dominant negative IB was from Dr. R. Gaynor (Uni-
versity of Texas Southwestern Medical Center, Houston, TX), the ex-
pression plasmid pRSV-NF-B (p65/RelA) was from Dr. D. Schmoll
(Sanofi Aventis Pharma) (30), and the expression vector for CK2 was
from Dr. R. Kemler (Max-Planck-Institute for Immunobiology,
Freiburg, Germany) (31). The plasmid pFA-CHOP with the transacti-
vation domain of the TF CHOP fused with the DNA-binding domain of
yeast Gal4 and the empty control vector pFC2-dbd were purchased from
Stratagene. The reporter gene construct pHO-347 Bmut, which con-
tains targeted mutations within the rat HO-1 proximal B site, was
generated with the template pHO-347 and the oligonucleotides
mutBfor (5-GAATTGTCTCCTAGTTCTCCTACCTTGGAGATTCC
TGAGAGGGC-3) as forward primer and mutBrev (5-GCCTCTCAG
GAATCTCCAAGGTAGGAGAACTAGGAGACAATTC-3) as re-
verse primer. The reporter construct pHO-347 MTE was generated with
the oligonucleotides (5-GAGCTTGCCAGAGCTATACAATTTATC
CCCATAC-3) as forward primer and (5-GTATGGGGATAAATTGTA
TAGCTGTGGCAAGCTC-3) as reverse primer and pHO-347 as tem-
plate. Both plasmids were generated with the QuikChange XL site-directed
mutagenesis kit (Stratagene) according to the manufacturer’s instructions.
Plasmid pHO-20 was generated from synthetic oligonucleotides containing
the rat HO-1 region from20 to 71 bp and XhoI or KpnI restriction sites
at their ends (MWG-Biotech). Annealed dsDNA was ligated into XhoI/
KpnI sites of pGL3basic (Promega) by using standard molecular cloning
methods. All constructs were verified by DNA sequencing in both
directions.
Transfection and luciferase assay
After growth for 24 h, transfection of plasmid DNA into RAW264.7
cells and MEF was performed by using FuGENE (Roche Applied Sci-
ence) as described previously (29). Unless otherwise mentioned, cells
were transfected with 0.5–1 g of the reporter plasmid and, in cotrans-
fection experiments, with 0.1–1 g of the indicated expression vectors.
Transfection efficiency was controlled using 0.1 g of Renilla lucif-
erase expression vector pRL-SV40 (Promega) as described previously
(29). Cells were lysed with luciferase lysis reagent (Promega) and lu-
ciferase activity was determined with a commercial Dual-Luciferase
reporter assay system (Promega) according to the manufacturer’s in-
structions. Cells were either harvested 24 h after transfection or treated
for the time points indicated with PMA or other reagents, as indicated.
Relative light units of Firefly luciferase activity were normalized with
Renilla luciferase activity.
Preparation of nuclear extracts (NE) and EMSA
NE were prepared as described previously (29). The sequences of the
biotin-labeled oligonucleotides (MWG-Biotech) used for the EMSA are
as follows: HO-B-B, (5-CCTAGTTCTGGAACCTTCCAGATTCCT
GA-3), HO-Bmutant (HO-B-Bmut), (5-CCTAGTTCTTTAACCG
TTAAGATTCCTGA-3), and NF-B consensus oligonucleotide with
sequence (5-AGTTGAGGGGACTTTCCCAGGC-3) with respective
oligonucleotides of the noncoding strand. For competition assays, an
excess of unlabeled oligonucleotide was added as indicated. After pre-
incubation for 10 min at room temperature, the biotin-labeled probe was
added and incubation was continued for another 20 min. For supershift
analysis, 3 l of an Ab directed against the NF-B p65 subunit (Cell
Signaling) was added to the EMSA reaction. The reaction mixture was
loaded on a 6% native polyacrylamide gel in 0.5% Tris-borate-EDTA
and blotted onto nylon membranes (Pierce). After UV-cross-linking, the
LightShift chemiluminescent EMSA kit (Pierce) was used to detect in-
teraction between the biotin end-labeled DNA and the protein with a
streptavidin-HRP conjugate and the chemiluminescent substrate.
Results
PMA induces endogenous HO-1 gene expression in
mononuclear phagocytes
To investigate the regulation of HO-1 gene expression by the
phorbol ester PMA in cell cultures of the monocytic cell line
RAW264.7, we determined mRNA levels of HO-1 after expo-
sure to PMA. For a comparison, the effect of PMA on HO-1
mRNA expression was also determined in primary rat LTM,
peritoneal macrophages, and hepatocytes. PMA induced HO-1
mRNA levels in RAW264.7 cells and to a similar extent also in
primary LTM (Fig. 1A) and peritoneal macrophages (data not
shown), but not in hepatocytes (Fig. 1A). Subsequently, we ex-
amined the effect of PMA on the regulation of endogenous
HO-1 protein expression in cell cultures of RAW264.7 cells and
LTM. Similarly as for the regulation of HO-1 mRNA levels in
response to PMA, HO-1 protein expression was markedly in-
duced by this treatment (Fig. 1B). It is also remarkable, that
PMA-dependent induction of HO-1 gene expression was ob-
served in human PBMC (Fig. 1B). The data indicate that PMA
induced HO-1 gene expression in the monocytic cell line
RAW264.7 and in various primary monocytic cells, but not in
hepatocytes.
The time course of HO-1 gene induction by PMA is different
from that by LPS in RAW264.7 cells
The proinflammatory mediator LPS has previously been shown
to be a potent inducer of HO-1 (32). To further investigate the
regulatory mechanism(s) of PMA-dependent induction of HO-1
in monocytic cells, we compared the time course of HO-1 pro-
tein expression by PMA with that elicited by LPS. Treatment
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with PMA induced HO-1 gene expression in RAW264.7 cells in
a time-dependent manner with a maximum after 6 h that per-
sisted up to 18 h, whereas LPS-dependent induction of HO-1
was retarded (Fig. 1C). Moreover, we have also determined the
combined effect of PMA and LPS on HO-1 gene expression.
Simultaneous treatment with PMA and LPS induced HO-1 gene
expression in an additive manner (Fig. 1D). The data suggest
that various mechanisms regulate HO-1 gene expression in re-
sponse to PMA and LPS in RAW264.7 cells.
Identification of a functional proximal B-site of the rat HO-1
promoter that mediates PMA-dependent induction of HO-1 gene
transcription
PMA is not only known to induce HO-1 gene expression (33),
but it also activates the NF-B pathway in monocytes (34). To
further study whether HO-1 induction by PMA could be medi-
ated via NF-B, we searched for potential B elements in the
proximal promoter region (positions 1338 to  1) of the rat
HO-1 gene. Two putative B elements, HO-B-A (1002 to
993) and HO-B-B (284 to 275), were identified. Both
elements matched the consensus sequence of the prototypical
B element in eight or nine of 10 nucleotides, respectively (Fig.
2A). In addition, a macrophage-specific 12-O-tetradecanoyl-
phorbol-13-acetate-responsive element (MTE), which has pre-
viously been shown to mediate PMA-dependent induction of
the human HO-1 gene (33), was identified in the proximal 5-
flanking sequence of the rat HO-1 gene promoter (140 to
131)(Fig. 2A).
To further characterize the HO-1 gene activation in response
to PMA, reporter gene constructs with serially 5-deleted
HO-1 promoter sequences were transiently transfected into
FIGURE 1. PMA-dependent induction of HO-1 gene
expression in monocytic cells. RAW264.7 cells (RAW),
LTM, hepatocytes (Hep), and human PBMC were cul-
tured as described under Materials and Methods. A,
Cells were treated with () or without () PMA (0.5
M) for 6 h in serum-free medium, as indicated. Total
cellular RNA (5 g) was isolated and subjected to
Northern blot analysis, and the blots were sequentially
probed with a 32P-labeled cDNA of rat HO-1 and a 28S
rRNA oligonucleotide. B, RAW264.7 cells, LTM, cells
and human (hu) PBMC were treated with PMA (0.5
M) or control medium for 6 h in serum-free medium.
C, RAW264.7 cells were treated with PMA (0.5 M),
LPS (1 g/ml), or control medium for the times indi-
cated. D, RAW264.7 cells were treated with PMA (0.5
M) and/or LPS for 18 h in serum-free medium, as
indicated. B–D, Total protein (50 g) was subjected to
Western blot analysis and sequentially probed with Abs
against HO-1 and GAPDH. A–D, Autoradiograms from
representative experiments are shown respectively. The
autoradiographic signals were scanned by video densi-
tometry and quantitated using ImageQuant software. A,
The signal of the 28S rRNA band served as internal
standard. Numbers show the fold induction rate relative
to control HO-1 mRNA expression from at least three
independent experiments SEM. B–D, Values  SEM
represent the fold-induction of HO-1 normalized to
GAPDH from three independent experiments. Statistics
and Student’s t test for paired values: , significant dif-
ferences for treatment vs control, p  0.05.
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RAW264.7 cells. Loss of the distal HO-B-A element in pHO-
754 and pHO-347 did not cause a major reduction of the PMA-
induced luciferase activity. By contrast, deletion of the
proximal HO-B-B site and the MTE in pHO-20 abrogated the
PMA-dependent induction, indicating a possible regulatory
function of these two elements (Fig. 2B).
To assess the regulatory capacity of the HO-B-B element and
the MTE, pHO-347 reporter gene constructs, either with or without
mutations of the B-B site and the MTE, were transfected into
RAW264.7 cells. Targeted mutations of the HO-B-B site led to a
marked reduction of PMA-dependent induction. By contrast, point
mutations of the MTE sequence did not have a major effect on
PMA-induced luciferase activity when compared with the wild-
type construct (Fig. 2C). It is also important to note that targeted
mutations within the HO-B-A site of pHO-1338 did not affect
PMA-dependent up-regulation of luciferase activity (data not
shown). Taken together, the data suggest that the HO-B-B site,
but not the MTE, mediate PMA-dependent induction of rat HO-1
gene expression.
The HO-B-B site is a target of NF-B
In EMSA studies we examined the binding activity of nuclear
proteins from RAW264.7 cells that were treated with either PMA
or LPS to an oligonucleotide with the HO-B-B site. NE from
PMA-treated cells showed markedly stronger DNA-binding activ-
ity to the HO-B-B oligonucleotide when compared with NE from
control cells. By contrast, NE from cells that were treated with
LPS only exhibited minor inducible DNA binding to the HO-B-B
site (Fig. 3A). The intensity of the band formed by the DNA-
protein complex of HO-B-B with NE from PMA-treated cells
was decreased by an excess of unlabeled HO-B-B oligonucleo-
tide in a dose-dependent manner (Fig. 3B). Binding of NE to the
HO-B-B site was abolished by an excess of unlabeled oligonu-
cleotides for HO-B-B and NF-B, respectively, but not by an
excess of an oligonucleotide with a targeted mutation in the HO-
B-B site (Fig. 3C). Moreover, incubation of the binding reaction
with an Ab against the NF-B subunit p65 caused a reduction of
DNA-protein complex formation (Fig. 3C), suggesting that the
HO-B-B site is a nuclear target for p65.
Overexpressed p65 induces HO-1 promoter activity
The NF-B subunit p65, which is also termed RelA, is a member
of the Rel family of proteins and is activated in response to a
variety of stimuli (18). To investigate the functional regulatory role
of p65 on HO-1 promoter activity, RAW264.7 cells were cotrans-
fected with HO-1 reporter gene constructs and an expression vec-
tor for p65. Basal luciferase activity of the reporter gene constructs
pHO-1338 and pHO-347, but not that of pHO-347Bmut with a
targeted mutation of the HO-B-B site, was markedly augmented
by overexpressed p65. As a control, luciferase activity of a reporter
gene plasmid with three copies of the prototypical B site (pNF-
B) was induced by cotransfected p65 to a similar extent when
compared with pHO-347 (Fig. 4). The data indicate that p65-de-
pendent HO-1 activation is mediated via the proximal HO-B-B
site of the rat HO-1 gene promoter.
HO-1 is not induced by PMA in p65/ MEF
To substantiate the involvement of NF-B and its subunit p65 in
PMA-dependent HO-1 induction, we examined the HO-1 gene ex-
pression in p65/ and p65/ MEF. We found that PMA was not
FIGURE 2. Identification of a functional B element
in the rat HO-1 promoter that mediates PMA-dependent
induction. A, Localization of the HO-B-A, HO-B-B,
and MTE sites within the rat HO-1 promoter and a se-
quence comparison with the NF-B consensus sequence
are shown. Mismatches to the prototypical NF-B con-
sensus sequence are bold and underlined. B and C, Lu-
ciferase (Luc) reporter gene constructs with the indi-
cated rat HO-1 promoter fragments were transfected
into RAW264.7 cells. Twenty-four hours after transfec-
tion, cells were treated with or without PMA (0.5 M)
for 18 h. Cell extracts were assayed for luciferase ac-
tivity and the fold induction relative to the control was
determined. Values are means  SEM from at least
three to four independent experiments with duplicates
of each point. Student’s t test for paired values: , sig-
nificant differences for PMA vs control (Ctrl); , pHO-
347 plus PMA vs pHO-20 plus PMA, p 0.05 (B); ,
pHO-347 plus PMA vs pHO-347Bmut plus PMA, p
0.05 (C).
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able to induce HO-1 expression in p65/ MEF that lack p65,
whereas PMA induced HO-1 expression in wild-type p65/ MEF
(Fig. 5A, left panel). Importantly, in p65/ MEF in which p65
was reconstituted by stable transfection with an expression vector
for p65 (27), PMA-dependent induction of HO-1 gene expression
was similar to that in wild-type cells (Fig. 5A). We also determined
PMA-dependent regulation of HO-1 promoter activity in p65/
and p65/ MEF. Luciferase activity of pHO-1338 was induced in
p65/ but not in p65/ MEF. Similar to the observations on
endogenous HO-1 gene regulation, PMA-dependent induction of
HO-1 promoter activity was restored in p65-reconstituted p65/
MEF (Fig. 5B). Taken together, the data confirm that p65 mediates
the transcriptional induction of PMA-dependent HO-1 gene
expression.
PMA-dependent HO-1 gene activation requires IB, but not
IKK2
The classical activation pathway of NF-B by proinflammatory
stimuli such as LPS and TNF- is mediated via IKK-dependent
phosphorylation of IB at serine 32 and serine 36. Phosphoryla-
tion of these regulatory serine residues leads to proteolysis of cy-
tosolic IB via the proteasome, after which p65/RelA is translo-
cated into the nucleus (18, 35). To investigate whether IB may
be involved in PMA-dependent induction of HO-1, we determined
the effect of overexpressed dominant negative IB on the level of
PMA-dependent HO-1 promoter induction. As demonstrated in
Fig. 6A, dominant negative IB markedly inhibited up-regulation
of HO-1 promoter activity by PMA. Moreover, PMA-dependent
induction of the control plasmid pTNF-585, which is known to be
regulated via functional B elements, was inhibited by dominant
negative IB to a similar extent.
To investigate the potential role of IKK2 for PMA-dependent
induction of HO-1 gene expression, we also determined the effect
of an overexpressed dominant negative mutant of IKK2 on HO-1
promoter activity. As shown in Fig. 6B, dominant negative IKK2
did not have an inhibitory effect on PMA-dependent up-regulation
of luciferase activity of pHO-1338, but markedly reduced PMA-
dependent induction of the control reporter gene construct pTNF-
585. No regulatory effect on PMA-dependent HO-1 promoter reg-
ulation was observed for the specific pharmacological IKK2
inhibitor SC-514 (data not shown).
To determine the PMA-dependent activation of IB,
RAW264.7 cells were not only treated with PMA but, for a com-
parison, also with LPS for various lengths of time, and cell extracts
were analyzed for the phosphorylation of IB at serine 32. Treat-
ment with LPS caused a marked increase of IB phosphorylation
at serine 32 for up to 8 h. In contrast, PMA induced IB phos-
phorylation at serine 32 only to a minor extent (Fig. 6C, upper
panel). Because it has previously been shown that IB can also
be phosphorylated at tyrosine 42 by oxidative stress (36, 37), we
also determined the phosphorylation of IB at this regulatory
residue in response to PMA and LPS. Treatment with PMA caused
a rapid and transient IB phosphorylation at tyrosine 42 after 15
min (second panel from top). In contrast, treatment with LPS
caused a stronger and more persistent IB phosphorylation at
tyrosine 42 as compared with PMA (Fig. 6C, second panel from
top).
FIGURE 3. Binding of nuclear proteins to the HO-B-B site. A, A bi-
otin-labeled oligonucleotide with the HO-B-B element was incubated
with 7 g of NE from control cells or from cells treated with PMA (0.5
M), LPS (1 g/ml), or without NE as a free probe. B, For competition
analyses the biotin-labeled HO-B-B oligonucleotide was preincubated
with 7 g of NE from PMA-treated cells along with a 10-, 50- and 100-fold
molar excess of unlabeled HO-B-B oligonucleotide, as indicated. C, Bi-
otin-labeled HO-B-B oligonucleotide was preincubated with 7 g of NE
from PMA-treated cells along with a 50-fold molar excess of unlabeled
HO-B-B or HO-B-Bmut or an oligonucleotide with the prototypical
NF-B site, as indicated. For supershift analysis, 3 or 5 l of Ab directed
against the NF-B subunit p65 was preincubated with NE from PMA-
treated cells before the biotin-labeled HO-B-B oligonucleotide was
added. DNA-protein complexes were separated by electrophoresis on a 6%
native polyacrylamide gel.
FIGURE 4. Effect of overexpressed p65 on HO-1 promoter activity.
RAW264.7 cells were cotransfected with luciferase reporter gene con-
structs pHO-1338, pHO-347, pHO-347 Bmut, pNF-B, and an expres-
sion vector for wild-type p65 or empty control expression vector (ev).
Twenty-four hours after transfection, luciferase assay and quantitation
were performed as described in Fig. 2. Values are means  SEM from
at least three or four independent experiments with duplicates of each
point. Student’s t test for paired values: , significant differences p65 vs
empty vector; , p65 plus pHO-347Bmut vs p65 plus pHO-347, p 
0.05.
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Taken together, the data suggest that PMA-dependent activation
of HO-1 is mediated via a nonclassical NF-B pathway that is
independent of IKK2 activity.
NAC attenuates HO-1 induction by PMA
PMA has previously been shown to up-regulate the generation of
reactive oxygen species (ROS) in monocytes (38). To determine
whether ROS as potential secondary messengers would be in-
volved in HO-1 gene induction in our cell culture model of
RAW264.7 cells, we examined the effect of the antioxidant NAC
on PMA-dependent induction of HO-1. Pretreatment with NAC
decreased PMA-dependent up-regulation of HO-1 in a dose-de-
pendent manner (Fig. 7A). Moreover, we also determined the effect
of NAC on the regulation of HO-1 promoter activity by PMA in
RAW264.7 cells. Pretreatment with NAC significantly lowered
PMA-induced promoter activity of the pHO-1338 reporter gene
construct (Fig. 7B), suggesting that the induction of HO-1 gene
expression by PMA is mediated via ROS.
p38 MAPK mediates PMA-dependent HO-1 gene induction
A major target of ROS in monocytes is p38 MAPK (39). Accord-
ingly, phosphorylation of p38 was markedly induced by PMA in
our model of RAW264.7 cells (Ref. 40 and data not shown). To
investigate the potential role of p38 MAPK for PMA-dependent
FIGURE 5. Regulation of HO-1 gene expression by PMA in p65-
deficient MEF. A, p65/, p65/, and p65/ MEF, in which p65 was
reconstituted (p65 recons), were cultured as described under Materials
and Methods and treated with PMA (0.5 M) or control medium for 6 h.
Western blot analysis and quantitation was performed as described in
Fig. 1B. Values  SEM represent the fold induction of HO-1 normal-
ized to GAPDH from three independent experiments. Statistics and Stu-
dent’s t test for paired values: , significant differences PMA vs control,
p  0.05. B, Cells were transiently transfected with the luciferase re-
porter gene construct pHO-1338 or empty control (Ctrl) vector
pGL3basic. Twenty-four hours after transfection cells were cultured for
another 18 h with or without PMA (0.5 M). Luciferase assay and
quantitation were performed as described in Fig. 2. Values are means 
SEM from at least three or four independent experiments with dupli-
cates of each point. Student’s t test for paired values: , significant
differences PMA vs control, p  0.05.
FIGURE 6. HO-1 promoter activation by PMA via an IB-depen-
dent but IKK2-independent pathway. A and B, RAW264.7 cells were
cotransfected with pHO-1338, pTNF-585, and an expression vector for
dominant negative IB (A), dominant negative IKK2 (B) or empty
control expression vectors (ev) (Ctrl, control), respectively. Twenty-
four hours after transfection cells were treated for 18 h with or without
PMA (0.5 M). Luciferase assay and quantitation was performed as
described in Fig. 2. Values are means  SEM from at least three in-
dependent experiments with duplicates of each point. Student’s t test for
paired values: , significant differences PMA vs control; , PMA plus
dominant negative IB (IBdn) vs PMA plus empty vector or PMA
plus dominant negative IKK2 (IKK2dn) vs PMA plus empty vector, p 
0.05. C, RAW 264.7 cells were treated with PMA (0.5 M), LPS (1
g/ml), or control medium for the times indicated. Total protein (50
g) was subjected to Western blot analysis and probed sequentially
with Abs against phosphorylated serine 32 (Ser 32 IB) and tyrosine
42 of IB (Tyr 42 IB), total IB, and GAPDH. Similar results
were obtained in three independent experiments and a representative
autoradiogram is shown.
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up-regulation of HO-1 gene expression, we determined the effect
of the pharmacological p38 inhibitor SB202190 on PMA-depen-
dent induction of endogenous HO-1 gene expression and promoter
activity. Pretreatment with SB202190 markedly decreased PMA-
dependent up-regulation of HO-1 gene expression (Fig. 8A). We
also examined the influence of this inhibitor on PMA-dependent
HO-1 promoter activity. Pretreatment with SB202190 significantly
attenuated the PMA-induced activity of the pHO-1338 reporter
gene construct (Fig. 8B). Taken together, the data suggest that p38
MAPK is involved in PMA-dependent induction of HO-1 gene
expression.
CK2 is involved in PMA-dependent HO-1 gene induction
CK2 is a stress-activated serine/threonine protein kinase (41, 42)
that has previously been shown to be involved in IKK2-indepen-
dent activation of NF-B (43). To investigate the potential regu-
latory role of CK2 for PMA-dependent up-regulation of HO-1
gene expression, we determined the effect of two specific CK2
inhibitors, RFBD and apigenin, on PMA-dependent induction of
endogenous HO-1 and promoter activity. Pretreatment with RFBD
and apigenin markedly reduced the PMA-dependent up-regulation
of HO-1 gene expression in a dose-dependent manner (Fig. 9, A
and B). Similar to the observations for endogenous HO-1 gene
regulation, pretreatment with RFBD or apigenin attenuated PMA-
dependent induction of HO-1 promoter activity (Fig. 9C). Finally,
we also evaluated the effect of cotransfection of an expression
vector for CK2 on basal HO-1 promoter activity. Overexpressed
CK2markedly augmented the activity of the HO-1 promoter con-
struct pHO-1338 and that of the control reporter gene plasmid
pNF-B (Fig. 9D). Thus, the data indicate that CK2 is involved in
the regulation of HO-1 gene induction by PMA.
CK2 is a downstream target of PMA-dependent p38 activation
Activation of CK2 by various stress stimuli such as UV light has
previously been shown to be regulated via p38 MAPK (43). To
determine whether p38 MAPK is required for PMA-dependent
CK2 activation, p38 MAPK activity was determined with a fusion
plasmid containing the transactivation domain of the transcription
factor CHOP and the DNA-binding domain of yeast Gal4 (pFA-
CHOP). Transactivation via pFA-CHOP is specifically controlled
FIGURE 7. Effect of NAC on HO-1 gene activation by PMA. A,
RAW264.7 cells were pretreated with NAC at concentrations of 2, 5, and
25 mM for 30 min, after which treatment was continued for another 6 h
with () or without () PMA (0.5 M). Western blot analysis and quan-
titation were performed as described in Fig. 1B. Values  SEM represent
the fold induction of HO-1 normalized to GAPDH from three independent
experiments. Statistics and Student’s t test for paired values: , significant
differences for PMA vs control; , PMA plus NAC vs PMA, p  0.05. B,
RAW264.7 cells were transfected with pHO-1338. Twenty-four hours after
transfection, cells were pretreated with NAC at concentrations of 5 or 25
mM for 30 min, after which treatment was continued for another 18 h with
or without PMA (0.5 M). Luciferase assay and quantitation was per-
formed as described in Fig. 2. Values are means SEM from at least three
independent experiments with duplicates of each point. Student’s t test for
paired values: , significant differences for PMA vs control; , PMA plus
NAC vs PMA, p  0.05.
FIGURE 8. Effect of p38 MAPK inhibitor SB202190 on PMA-depen-
dent HO-1 gene activation. A, RAW264.7 cells were pretreated with
SB202190 (5 and 10 M) for 30 min, after which treatment was continued
for another 6 h with () or without) PMA (0.5 M). Western blot anal-
ysis and quantitation were performed as described in Fig. 1B. Values 
SEM represent the fold induction of HO-1 normalized to GAPDH from
three independent experiments. Statistics and Student’s t test for paired
values: , significant differences PMA vs control; , PMA plus SB202190
vs PMA, p  0.05. B, RAW264.7 cells were transfected with pHO-1338.
Twenty-four hours after transfection cells were treated with SB202190 at
a concentration of 10 M for 30 min, after which treatment was continued
for another 18 h with or without PMA (0.5 M). Luciferase assay and
quantitation were performed as described in Fig. 2. Values are means 
SEM from at least three independent experiments with duplicates of each
point. Student’s t test for paired values: , significant differences PMA vs
control; , PMA plus SB202190 vs PMA, p  0.05.
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by p38-dependent phosphorylation of two adjacent regulatory
serine residues of the CHOP transactivation domain (44). Treat-
ment with PMA strongly induced pFA-CHOP activity, and pre-
treatment with the p38 MAPK inhibitor SB202190 lowered PMA-
dependent pFA-CHOP-mediated luciferase activity. By contrast,
pretreatment with CK2 inhibitors had no effect on PMA-depen-
dent, pFA-CHOP-mediated luciferase activity (Fig. 10), suggest-
ing that p38 MAPK is an upstream kinase of PMA-dependent CK2
activation.
Discussion
Expression of HO-1 is up-regulated by multiple stress stimuli, and
the enzymatic products of this reaction not only have antioxidant
cytoprotective effects but also anti-inflammatory functions in var-
ious animal models (10–15). The present study demonstrates the
following: 1) HO-1 is induced by PMA in monocytic cells with a
regulatory pattern different from that by LPS; 2) HO-1 induction
by PMA occurs on the transcriptional level and is mediated via a
proximal B site of the rat HO-1 promoter that is a nuclear target
of p65/RelA; and 3) an IKK-independent, atypical NF-B pathway
mediates PMA-dependent induction of HO-1 via activation of p38
MAPK and CK2.
Transcriptional induction of HO-1 gene expression by PMA
In the present report it is shown that HO-1 gene expression is
induced by PMA in monocytic cells, but not in hepatocytes (Fig.
1A). These findings correspond with a previous report demonstrat-
ing that PMA induced HO-1 gene expression in a monocyte-spe-
cific manner in human myelomonocytic cells (33). The regulatory
mechanism(s) that mediate(s) HO-1 gene induction by PMA ap-
pear(s) to be different from that by LPS, because HO-1 gene ex-
pression was up-regulated with a different time course by these two
compounds (Fig. 1C). This assumption is also supported by the
observation that simultaneous treatment with PMA and LPS in-
duced HO-1 gene expression in an additive manner (Fig. 1D).
Distinct kinetics of gene induction by PMA and LPS were also
reported for cyclooxygenase-2 gene expression in monocytes (26,
45). The different kinetics of HO-1 gene induction by PMA and
FIGURE 9. Effect of CK2 on PMA-dependent HO-1
gene activation. A and B, RAW264.7 cells were pre-
treated with RFBD (A) and apigenin (B) at increasing
concentrations (M) for 30 min, after which treatment
was continued for another 6 h with () or without ()
PMA (0.5 M). Western blot analysis and quantitation
were performed as described in Fig. 1B. Values  SEM
represent the fold induction of HO-1 normalized to
GAPDH from three independent experiments. Statistics
and Student’s t test for paired values: , significant dif-
ferences PMA versus control; , PMA plus RFBD vs
PMA and PMA plus apigenin vs PMA, p  0.05. C,
RAW264.7 cells were transiently transfected with pHO-
1338. Twenty-four hours after transfection cells were
treated with RFBD and apigenin (25 M, respectively)
for 30 min, after which treatment was continued for an-
other 18 h with or without PMA (0.5 M). Luciferase
assay and quantitation were performed as described in
Fig. 2. Values are means  SEM from at least three
independent experiments with duplicates of each point.
Student’s t test for paired values: , significant differ-
ences PMA vs control; , PMA plus RFBD vs PMA
and PMA plus apigenin vs PMA, p  0.05. D,
RAW264.7 cells were cotransfected with pHO-1338,
pNF-B, and an expression vector for CK2 or empty
control expression vector (ev). Twenty-four hours after
transfection, luciferase assay and quantitation was per-
formed as described in Fig. 2. Values are means SEM
from at least three independent experiments with dupli-
cates of each point. Student’s t test for paired values: ,
significant differences CK2 vs empty vector, p  0.05.
FIGURE 10. Regulation of PMA-dependent induction of CHOP trans-
activity by inhibition of p38 and CK2. RAW264.7 cells were cotransfected
with the luciferase reporter gene construct pGal4-luc, pFC2-dbd, or pFA-
CHOP, as indicated. Twenty-four hours after transfection, cells were
treated with PMA (0.5 M), SB202190 (10 M), or the CK2 inhibitors
RFBD (25 M) and apigenin (25 M), as indicated. Cell extracts were
assayed for luciferase activity, and the fold induction relative to the control
was determined. Values are means  SE from at least three independent
experiments with duplicates of each point. Student’s t test for paired val-
ues: , significant differences treatment vs control; , SB202190 plus
PMA vs PMA, p  0.05.
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LPS may also correspond with the distinct binding of nuclear
proteins to the HO-B-B site (Fig. 3).
Identification of a functional B site in the rat HO-1 gene
promoter
Activation of the TF NF-B is a major pathway for mediating
cell survival during oxidative stress (18). Because multiple
stress stimuli that are known to induce HO-1 gene expression
also activate NF-B (19 –21), we hypothesized that the HO-1
promoter may be targeted by this TF. Two potential B sites
within the proximal rat HO-1 gene promoter have been identi-
fied that share high sequence identity with the prototypical
NF-B consensus sequence (5-GGGRNNYYCC-3) (Fig. 2A).
Although two potential candidate B elements were found, we
demonstrate that PMA-dependent induction of HO-1 promoter
activity was only mediated via the proximal HO-B-B site. In
addition, it is shown that this HO-B-B element was a nuclear
target for the NF-B subunit p65/RelA (Figs. 2– 4). Although
NF-B has been implicated in the transcriptional regulation of
HO-1 gene expression (17), to our knowledge the rat HO-B-B
site is the first functional RE of the HO-1 gene that is directly
targeted by NF-B. In an earlier report on the human HO-1
gene promoter, a putative B site has been shown to exhibit in
vitro DNA-binding with the recombinant NF-B subunit p50,
but the functionality of this RE has not been examined (46). In
other reports, the in vitro binding activity of nuclear proteins to
synthetic NF-B oligonucleotides, which were not necessarily
found in the HO-1 gene promoter, have been correlated with the
induction of HO-1 gene expression by various identical stimuli
(17, 21, 47). It is conceivable that a functional HO-1 B ele-
ment may have been overlooked in earlier studies, because hu-
man and mouse HO-1 gene promoter regions, which have pre-
viously been studied in more detail, exhibit significant sequence
differences when compared with the rat HO-1 gene promoter.
Sequence alignment of the first 1338 bp of the promoter 5-
flanking region of the rat, mouse, and human HO-1 genes re-
vealed only 47% (rat vs human), 49% (mouse vs human), and
69% (rat vs mouse) sequence similarity, respectively. Remark-
ably, the murine sequence corresponding to the functional rat
HO-B-B element did not contain a homologous B sequence,
which may suggest species-specific functionality of the HO-
B-B site. Independently, the rat sequence that corresponds
with a previously identified PMA-responsive MTE of the hu-
man HO-1 promoter (33) was not functional in the context of
the rat HO-1 gene promoter (Fig. 2). In conclusion, discrepan-
cies of the promoter structure may explain species-specific dif-
ferences of HO-1 gene regulation that have also been observed
for HO-1 induction by hypoxia or heat shock (17, 48). The
present study, however, does not exclude the possibility that
PMA-dependent induction of HO-1 is regulated by TF other
than NF-B. In fact, the TF AP-1 and Nrf2 have also been
shown to mediate PMA-dependent induction of the mouse
HO-1 gene (49, 50).
Signaling pathway of PMA-dependent HO-1 gene induction
The classical NF-B pathway is regulated via IKK-dependent
phosphorylation of serine 32 and 36 in the N-terminal region of
IB in response to a variety of stimuli such as LPS and TNF-
(18, 35). Accordingly, inhibition of PMA-dependent HO-1 pro-
moter activation by overexpressed dominant negative IB, but
not by dominant negative IKK2 (Fig. 6), indicated that the clas-
sical NF-B pathway does not play a major role for this regu-
lation. This conclusion is consistent with the observation that
IB is phosphorylated to a minor extent at serine 32 in re-
sponse to PMA rather than in response to LPS (Fig. 6C).
Furthermore, it has been proposed that ROS could be in-
volved in the activation of atypical NF-B regulatory pathways,
because PMA could increase intracellular levels of ROS in
mononuclear phagocytes (38) and affect the phosphorylation of
IB at tyrosine 42 (36, 37). In line with this proposal, we
showed in the present study that the action of PMA on HO-1
gene expression was abolished by treatment with the antioxi-
dant NAC (Fig. 7), which indicates the involvement of ROS.
We also examined whether PMA would affect phosphorylation
of IB at tyrosine 42 and found a minor and transient level of
IB phosphorylation at tyrosine 42 after treatment with PMA
(Fig. 6C). This minor up-regulation of IB phosphorylation at
tyrosine 42 did not correlate with the marked PMA-dependent
induction of HO-1 gene expression (Fig. 1) and the inducible
DNA binding of nuclear extracts to the HO-B site in response
to PMA (Fig. 3). Therefore, IB phosphorylation at tyrosine
42 does not seem to play a major role for PMA-dependent in-
duction of HO-1 gene expression. These latter observations may
correspond with a report, in which H2O2 has been demonstrated
to stimulate NF-B, but phosphorylation of IB at tyrosine 42
per se was not sufficient for NF-B activation (36). Moreover,
PMA as a prototypical activator of PKC, which mimics the
intracellular effects of the endogenous mediator diacylglycerol
(23), has recently been found to activate PKC in a p38 MAPK-
dependent manner (51). This assumption would partially cor-
respond with our data on PMA-dependent induction of HO-1
gene expression by NF-B via ROS and a p38 MAPK/CK2-
dependent pathway (Figs. 7–10). Thus, the present study
strongly suggests that this signaling cascade is mediated via an
atypical NF-B pathway that involves phosphorylation of reg-
ulatory sites in the C-terminal domain of IB. A similar reg-
ulatory signaling cascade has previously been shown for the
activation of NF-B by UV light in HeLa cells (43).
Physiological significance of PMA-dependent HO-1 gene
induction in monocytes
The findings of our present study, along with those of a previ-
ous report (33) that demonstrate a monocyte-specific induction
of HO-1 gene expression by PMA, suggest an important phys-
iological role of PKC-dependent HO-1 up-regulation in mono-
cyte differentiation and/or activation. This assumption would
correspond with a recent study in which it has been shown that
the activation of PKC is essential for the differentiation of
CD14 monocytes into macrophages or dendritic cells (52).
Moreover, the proinflammatory mediator LPS has recently been
shown to exert its cellular effect via activation of PKC and
NF-B in macrophages, which may also involve the induction
of HO-1 gene expression (53).
Inflammatory processes play a major role in the pathogenesis
of cancer and cardiovascular disease. Evidence has accumulated
that HO-1 has potent anti-inflammatory functions, because ge-
netic HO-1 deficiency causes a chronic inflammatory phenotype
and high vulnerability to LPS (7, 9). Anti-inflammatory protec-
tion via the induction of HO-1 has initially been described in a
model of acute complement-dependent pleurisy (54). More re-
cently, the potential clinical relevance of HO-1 has also been
shown in various animal models of inflammatory diseases and
organ transplantation, in which targeted overexpression of
HO-1 provided efficient protection (10 –15, 55). Finally, it is
remarkable that HO-1 gene expression is not only regulated via
NF-B as demonstrated in the present report, but that HO-1 can
modulate the activity of NF-B in various cell types (56 –58).
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In conclusion, the present study defines a new regulatory mech-
anism of HO-1 gene expression by PMA in monocytic cells and
may help to further understand the complexity of the gene regu-
lation of this protective gene.
Acknowledgments
We thank Silke Werth and Annette Zeyer for excellent technical assistance.
We also thank Dr. Gordon Duff, Dr. Richard Gaynor, Dr. Rolf Kemler, and
Dr. Dieter Schmoll for supply of plasmids and Dr. Hiroyasu Nakano for
providing p65-deficient fibroblasts.
Disclosures
The authors have no financial conflict of interest.
References
1. Tenhunen, R., H. S. Marver, and R. Schmid. 1968. The enzymatic conversion of
heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. USA 61:
748–755.
2. Maines, M. D. 1997. The heme oxygenase system: a regulator of second mes-
senger gases. Annu. Rev. Pharmacol. Toxicol. 37: 517–554.
3. Stocker, R., Y. Yamamoto, A. F. McDonagh, A. N. Glazer, and B. N. Ames.
1987. Bilirubin is an antioxidant of possible physiological importance. Science
235: 1043–1046.
4. Kutty, R. K., and M. D. Maines. 1981. Purification and characterization of biliv-
erdin reductase from rat liver. J. Biol. Chem. 256: 3956–3962.
5. Otterbein, L. E., F. H. Bach, J. Alam, M. P. Soares, L. H. Tao, M. Wysk,
R. J. Davis, R. A. Flavell, and A. M. Choi. 2000. Carbon monoxide has anti-
inflammatory effects involving the mitogen-activated protein kinase pathway.
Nat. Med. 6: 422–428.
6. Ryter, S. W., J. Alam., and A. M. Choi. 2006. Heme oxygenase-1/carbon
monoxide: From basic science to therapeutic applications. Physiol. Rev. 86:
583– 650.
7. Poss, K. D., and S. Tonegawa. 1997. Reduced stress defense in heme oxygenase
1-deficient cells. Proc. Natl. Acad. Sci. USA 94: 10925–10930.
8. Yachie, A., Y. Niida, T. Wada, N. Igarashi, H. Kaneda, T. Toma, K. Ohta,
Y. Kasahara, and S. Koizumi. 1999. Oxidative stress causes enhanced endo-
thelial cell injury in human heme oxygenase-1 deficiency. J. Clin. Invest. 103:
129 –135.
9. Tracz, M. J., J. P. Juncos, J. P. Grande, A. J. Croatt, A. W. Ackerman,
G. Rajagopalan, K. L. Knutson, A. D. Badley, M. D. Griffin, et al. 2007. Renal
hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in
HO-1/ mice. Am. J. Pathol. 170: 1820–1830.
10. Immenschuh, S., and G. Ramadori. 2000. Gene regulation of heme oxygenase-1
as a therapeutic target. Biochem. Pharmacol. 60: 1121–1128.
11. Abraham, N. G., A. Asija, G. Drummond, and S. Peterson. 2007. Heme oxygen-
ase-1 gene therapy: recent advances and therapeutic applications. Curr. Gene
Ther. 7: 89–108.
12. Orozco, L. D., M. H. Kapturczak, B. Barajas, X. Wang, M. M. Weinstein,
J. Wong, J. Deshane, S. Bolisetty, Z. Shaposhnik, D. M. Shih, et al. 2007. Heme
oxygenase-1 expression in macrophages plays a beneficial role in atherosclerosis.
Circ. Res. 100: 1703–1711.
13. Pamplona, A., A. Ferreira, J. Balla, V. Jeney, G. Balla, S. Epiphanio, A. Chora,
C. D. Rodrigues, I. P. Gregoire, M. Cunha-Rodrigues, et al. 2007. Heme oxy-
genase-1 and carbon monoxide suppress the pathogenesis of experimental cere-
bral malaria. Nat. Med. 13: 703–710.
14. Chora, A. A., P. Fontoura, A. Cunha, T. F. Pais, S. Cardoso, P. P. Ho, L. Y. Lee,
R. A. Sobel, L. Steinman, and M. P. Soares. 2007. Heme oxygenase-1 and carbon
monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117:
438–447.
15. Chung, S. W., X. Liu, A. A. Macias, R. M. Baron, and M. A. Perrella. 2008.
Heme oxygenase-1-derived carbon monoxide enhances the host defense response
to microbial sepsis in mice. J. Clin. Invest. 118: 239–247.
16. Choi, A. M., and J. Alam. 1996. Heme oxygenase-1: function, regulation, and
implication of a novel stress-inducible protein in oxidant-induced lung injury.
Am. J. Respir. Cell Mol. Biol. 15: 9–19.
17. Alam, J., and J. L. Cook. 2007. How many transcription factors does it
take to turn on the heme oxygenase-1 gene? Am. J. Respir. Cell Mol. Biol. 36:
166 –174.
18. Perkins, N. D., and T. D. Gilmore. 2006. Good cop, bad cop: the different faces
of NF-B. Cell Death Differ. 13: 759–772.
19. Hill-Kapturczak, N., V. Thamilselvan, F. Liu, H. S. Nick, and A. Agarwal. 2001.
Mechanism of heme oxygenase-1 gene induction by curcumin in human renal
proximal tubule cells. Am. J. Physiol. 281: F851–F859.
20. Wijayanti, N., S. Huber, A. Samoylenko, T. Kietzmann, and S. Immenschuh.
2004. Role of NF-B and p38 MAP kinase signaling pathways in the lipopo-
lysaccharide-dependent activation of heme oxygenase-1 gene expression. Anti-
oxid. Redox Signal. 6: 802–810.
21. Andreadi, C. K., L. M. Howells, P. A. Atherfold, and M. M. Manson. 2006.
Involvement of Nrf2, p38, B-Raf, and nuclear factor-B, but not phosphatidyl-
inositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol.
Pharmacol. 69: 1033–1040.
22. Wu, W. T., K. H. Chi, F. M. Ho, W. C. Tsao, and W. W. Lin. 2004. Proteasome
inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38
MAPK (mitogen-activated protein kinase) activation but not of NF-B (nuclear
factor B) inhibition. Biochem. J. 379: 587–593.
23. Gopalakrishna, R., and S. Jaken. 2000. Protein kinase C signaling and oxidative
stress. Free Radic. Biol. Med. 28: 1349–1361.
24. Immenschuh, S., J. Stritzke, S. Iwahara, and G. Ramadori. 1999. Up-regulation
of heme-binding protein 23 (HBP23) gene expression by lipopolysaccharide is
mediated via a nitric oxide-dependent signaling pathway in rat Kupffer cells.
Hepatology 30: 118–127.
25. Immenschuh, S., T. Kietzmann, V. Hinke, M. Wiederhold, N. Katz, and
U. Muller-Eberhard. 1998. The rat heme oxygenase-1 gene is transcriptionally
induced via the protein kinase A signaling pathway in rat hepatocyte cultures.
Mol. Pharmacol. 53: 483–491.
26. Wijayanti, N., T. Kietzmann, and S. Immenschuh. 2005. Heme oxygenase-1 gene
activation by the NAD(P)H oxidase inhibitor 4-(2-aminoethyl) benzenesulfonyl
fluoride via a protein kinase B, p38-dependent signaling pathway in monocytes.
J. Biol. Chem. 280: 21820–21829.
27. Okazaki, T., S. Sakon, T. Sasazuki, H. Sakurai, T. Doi, H. Yagita, K. Okumura,
and H. Nakano. 2003. Phosphorylation of serine 276 is essential for p65 NF-B
subunit-dependent cellular responses. Biochem. Biophys. Res. Commun. 300:
807–812.
28. Kietzmann, T., A. Samoylenko, and S. Immenschuh. 2003. Transcriptional reg-
ulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and
p38 pathways in primary cultures of rat hepatocytes. J. Biol. Chem. 278:
17927–17936.
29. Wijayanti, N., S. Naidu, T. Kietzmann, and S. Immenschuh. 2008. Inhibition of
phorbol ester-dependent peroxiredoxin I gene activation by lipopolysaccharide
via phosphorylation of RelA/p65 at serine 276 in monocytes. Free Radic. Biol.
Med. 44: 699–710.
30. Grempler, R., A. Kienitz, T. Werner, M. Meyer, A. Barthel, F. Ailett,
C. Sutherland, R. Walther, and D. Schmoll. 2004. Tumor necrosis factor  de-
creases glucose-6-phosphatase gene expression by activation of nuclear factor
B. Biochem. J. 382: 471–479.
31. Bek, S., and R. Kemler. 2002. Protein kinase CKII regulates the interac-
tion of -catenin with -catenin and its protein stability. J. Cell Sci. 115:
4743– 4753.
32. Camhi, S. L., J. Alam, L. Otterbein, S. L. Sylvester, and A. M. Choi. 1995.
Induction of heme oxygenase-1 gene expression by lipopolysaccharide is medi-
ated by AP-1 activation. Am. J. Respir. Cell Mol. Biol. 13: 387–398.
33. Muraosa, Y., and S. Shibahara. 1993. Identification of a cis-regulatory element
and putative trans-acting factors responsible for 12-O-tetradecanoylphorbol-13-
acetate (TPA)-mediated induction of heme oxygenase expression in myelomono-
cytic cell lines. Mol. Cell. Biol. 13: 7881–7891.
34. Shin, Y. H., J. J. Shim, M. W. Hur, C. J. Kang, and J. Kim. 2004. Involvement
of two NF-B binding sites in PMA-induced expression of the human leukotac-
tin-1/CCL15 gene in U937 monocytoid cells. Mol. Cells 17: 316–321.
35. Chen, L. F., and W. C. Greene. 2004. Shaping the nuclear action of NF-B. Nat.
Rev. Mol. Cell Biol. 5: 392–401.
36. Livolsi, A., V. Busuttil, V. Imbert, R. T. Abraham, and J. F. Peyron. 2001.
Tyrosine phosphorylation-dependent activation of NF-B: recruitment for
p56 LCK and ZAP-70 protein tyrosine kinases. Eur. J. Biochem. 268:
1508 –1515.
37. Takada, Y., A. Mukhopadhyay, G. C. Kundu, G. H. Mahabeleshwar, S. Singh,
and B. B. Aggarwal. 2003. Hydrogen peroxide activates NF-B through tyrosine
phosphorylation of IB and serine phosphorylation of p65: evidence for the
involvement of IB kinase and Syk protein-tyrosine kinase. J. Biol. Chem. 278:
24233–24241.
38. Datta, R., K. Yoshinaga, M. Kaneki, P. Pandey, and D. Kufe. 2000.
Phorbol ester-induced generation of reactive oxygen species is protein kinase
C -dependent and required for SAPK activation. J. Biol. Chem. 275:
41000 – 41003.
39. Roux, P. P., and J. Blenis. 2004. ERK and p38 MAPK-activated protein kinases:
a family of protein kinases with diverse biological functions. Microbiol. Mol.
Biol. Rev. 68: 320–344.
40. Hess, A., N. Wijayanti, A. P. Neuscha¨fer-Rube, N. Katz, T. Kietzmann, and
S. Immenschuh. 2003. Phorbol ester-dependent activation of peroxiredoxin I
gene expression via a protein kinase C, Ras, p38 mitogen-activated protein kinase
signaling pathway. J. Biol. Chem. 278: 45419–45434.
41. Litchfield, D. W. 2003. Protein kinase CK2: structure, regulation, and role in
cellular decisions of life and death. Biochem. J. 369: 1–15.
42. Sayed, M., S. O. Kim, B. S. Salh, O. G. Issinger, and S. L. Pelech. 2000. Stress-
induced activation of protein kinase CK2 by direct interaction with p38 mitogen-
activated protein kinase. J. Biol. Chem. 275: 16569–16573.
43. Kato, T., Jr., M. Delhase, A. Hoffmann, and M. Karin. 2003. CK2 is a C-Terminal
IkappaB kinase responsible for NF-B activation during the UV response. Mol.
Cell 12: 829–839.
44. Wang, X. Z., and D. Ron. 1996. Stress-induced phosphorylation and activation of
the transcription factor CHOP (GADD153) by p38 MAP Kinase. Science 272:
1347–1349.
45. Chun, K. S., and Y. J. Surh. 2004. Signal transduction pathways regulating cy-
clooxygenase-2 expression: potential molecular targets for chemoprevention.
Biochem. Pharmacol. 68: 1089–1100.
46. Lavrovsky, Y., M. Schwartzman, R. D. Levere, A. Kappas, and N. G. Abraham.
1994. Identification of binding sites for transcription factors NF-B and AP-2 in
the promoter region of the human heme oxygenase 1 gene. Proc. Natl. Acad. Sci.
USA 91: 5987–5991.
4122 HEME OXYGENASE-1 GENE INDUCTION VIA NF-B IN MONOCYTES
47. Kurata, S., M. Matsumoto, and H. Nakajima. 1996. Transcriptional control of the
heme oxygenase gene in mouse M1 cells during their TPA-induced differentia-
tion into macrophages. J. Cell. Biochem. 62: 314–324.
48. Shibahara, S., M. Nakayama, T. Kitamuro, R. Udono-Fujimori, and
K. Takahashi. 2003. Repression of heme oxygenase-1 expression as a defense
strategy in humans. Exp. Biol. Med. 228: 472–473.
49. Alam, J., and D. Zhining. 1992. Distal AP-1 binding sites mediate basal level
enhancement and TPA induction of the mouse heme oxygenase-1 gene. J. Biol.
Chem. 267: 21894–21900.
50. Numazawa, S., M. Ishikawa, A. Yoshida, S. Tanaka, and T. Yoshida. 2003.
Atypical protein kinase C mediates activation of NF-E2-related factor 2 in re-
sponse to oxidative stress. Am. J. Physiol. 285: C334–C342.
51. Yin, L., N. Bennani-Baiti, and C. T. Powell. 2005. Phorbol ester-induced apo-
ptosis of C4–2 cells requires both a unique and a redundant protein kinase C
signaling pathway. J. Biol. Chem. 280: 5533–5541.
52. Lin, Y. F., H. M. Lee, S. J. Leu, and Y. H. Tsai. 2007. The essentiality of PKC
and PKCI translocation for CD14 monocyte differentiation towards macro-
phages and dendritic cells, respectively. J. Cell. Biochem. 102: 429–441.
53. Zhou, X., W. Yang, and J. Li. 2006. Ca2- and protein kinase C-dependent
signaling pathway for nuclear factor-B activation, inducible nitric-
oxide synthase expression, and tumor necrosis factor- production in lipopo-
lysaccharide-stimulated rat peritoneal macrophages. J. Biol. Chem. 281:
31337–31347.
54. Willis, D., A. R. Moore, R. Frederick, and D. A. Willoughby. 1996. Heme ox-
ygenase: a novel target for the modulation of the inflammatory response. Nat.
Med. 2: 87–90.
55. Soares, M. P., and F. H. Bach. 2007. Heme oxygenase-1 in organ transplantation.
Front. Biosci. 12: 4932–4945.
56. Seldon, M. P., G. Silva, N. Pejanovic, R. Larsen, I. P. Gregoire, J. Filipe,
J. Anrather, and M. P. Soares. 2007. Heme oxygenase-1 inhibits the expres-
sion of adhesion molecules associated with endothelial cell activation via
inhibition of NF-B RelA phosphorylation at serine 276. J. Immunol. 179:
7840 –7851.
57. Sarady, J. K., S. L. Otterbein, F. Liu, L. E. Otterbein, and A. M. Choi. 2002.
Carbon monoxide modulates endotoxin-induced production of granulocyte mac-
rophage colony-stimulating factor in macrophages. Am. J. Respir. Cell Mol. Biol.
27: 739–745.
58. Lin, Q., S. Weis, G. Yang, Y. H. Weng, R. Helston, K. Rish, A. Smith,
J. Bordner, T. Polte, F. Gaunitz, and P. A. Dennery. 2007. Heme oxygenase-1
protein localizes to the nucleus and activates transcription factors important in
oxidative stress. J. Biol. Chem. 282: 20621–20633.
4123The Journal of Immunology
Results and Discussion
17
3.1. Role of p38 MAPK for the regulation of HO-1 gene expression (Paper  III)
Although p38 MAPK is considered to be a major mediator of HO-1 gene 
activation by a host of stimuli (Ryter et al., 2006), it has been suggested that p38 may 
play an inhibitory role for HO-1 gene expression (Yu et al., 2000, Keum et al., 2006).
The present study demonstrated that pharmacological inhibition of p38 in monocytic 
cells and genetic deficiency of p38α in mouse embryonic fibroblasts (MEFs) up-
regulated HO-1 gene expression, but not that of Cox-2 (Figure 1, paper III). 
Activation of HO-1 gene expression by inhibition of p38 was regulated at the 
transcriptional level and mediated via a StRE of the mouse HO-1 gene promoter that 
served as a nuclear target for the stress-inducible TF Nrf2 (Figures 4, 6 and 7, paper 
III). Thus, these findings would agree with the findings of Yu et al., 2000 and Keum 
et al., 2006.
Pharmacological inhibition or genetic deficiency of p38 MAPK up-regulated ERK 
activity. In addition, pharmacological blockage of ERK in p38α-deficient MEF 
attenuated HO-1 expression, suggesting cross-talk between these two signaling 
pathways for the regulation of HO-1 expression (Figure 8, paper III). In accordance 
with these findings, previous studies have independently demonstrated an inhibitory 
role of p38 for ERK (Singh et al., 1999) and JNK (Elbirt et al., 1998). These 
observations may suggest that p38 MAPK is an important up-stream regulator of ERK 
and JNK.
Recent studies have also indicated that p38 may serve as a sensor of the cellular 
redox balance (Dolado et al., 2007). Accordingly, deficiency of p38 has been shown 
to cause an increased generation of ROS, which agrees with the findings of the 
present study (Figure 9, paper III). It is conceivable that intracellular ROS levels that 
are increased by p38 deficiency are responsible for the activation of ERK. This 
hypothesis may be supported by a study showing that, ROS mediate sustained 
activation of ERK in human hepatoma HepG2 cells (Wu et al., 2006).  
In summary, inhibition and genetic deficiency of p38 activates HO-1 gene 
expression via a transcriptional mechanism, which involves the redox-dependent TF 
Nrf2 (Figure 7), suggesting that p38 MAPK may play a dual role for the regulation of 
HO-1 gene expression. 
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Figure 7: Inhibition of p38 MAPK activates HO-1 gene expression
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ABSTRACT                         
Heme oxygenase (HO)-1 is the inducible isoform of the first and rate-limiting enzyme of heme 
degradation. The HO products carbon monoxide and bilirubin not only provide antioxidant 
cytoprotection, but also have potent anti-inflammatory and immunomodulatory functions. 
Although HO-1 has previously been shown to be induced by various stimuli via activation of the 
p38 MAPK signaling pathway, the role of this protein kinase for HO-1 gene regulation is largely 
unknown. In the present study it is demonstrated that pharmacological inhibitors of p38 induced 
HO-1 expression in monocytic cells. Moreover, basal HO-1 gene expression levels were 
markedly higher in untreated murine embryonic fibroblasts (MEF) from p38α-/- mice as 
compared to that from wild type mice. Transfection studies with luciferase reporter gene 
constructs indicate that increased HO-1 gene expression via inhibition of p38 was mediated by 
the transcription factor NF-E2-related factor- 2 (Nrf2), which is a central regulator of the cellular 
oxidative stress response. Accordingly, inhibitors of p38 induced binding of nuclear proteins to a 
Nrf2 target sequence of the HO-1 promoter, but did not affect HO-1 protein expression and 
promoter activity in Nrf2-/- MEF. Genetic deficiency of p38 led to enhanced phosphorylation of 
ERK and increased cellular accumulation of reactive oxygen species (ROS). In addition, 
pharmacological blockage of ERK and scavenging of ROS with N-acetylcysteine reduced HO-1 
gene expression in p38-/- MEF, respectively. Taken together, it is demonstrated that 
pharmacological inhibition and genetic deficiency of p38 induce HO-1 gene expression via a 
Nrf2-dependent mechanism in monocytic cells and MEF. 
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INTRODUCTION                  
Heme oxygenase (HO)-1 is the inducible isoform of the first and rate-controlling enzyme of 
heme degradation (1). HO-1 is induced by a variety of oxidative stress stimuli and exerts potent 
antioxidant and anti-inflammatory effects via its products bilirubin and carbon monoxide (CO) 
(2, 3). The anti-inflammatory functions of HO-1 have been described in HO-1 knockout mice (4, 
5) and have essentially been confirmed in a human case of genetic HO-1 deficiency (6). HO-1 
deficient mice exhibit a disproportional activation of monocytes and are highly vulnerable to 
endotoxin-mediated toxicity (4, 7). The potential significance of HO-1 in the adaptive immune 
system has been implied by a recent report, in which genetic deficiency of HO-1 decreased the 
suppressive activity of regulatory T cells (8). Importantly, overexpression of HO-1 either by 
gene transfer or by pharmacological inducers has beneficial effects in various animal models of 
inflammatory disease (3, 9-13). 
The up-regulation of HO-1 gene expression and that of other genes during inflammation and in 
response to pharmacological stimuli is mediated by a network of signaling pathways, among 
which MAPK play a central role (14). Three major subfamilies of MAPK are known: ERK, JNK 
and p38. While ERK mainly mediates cellular responses to hormones and growth factors, JNK 
and p38 are primarily activated by stress-related stimuli (14). Immunologically active cells such 
as monocytes and T cells display a high content of p38 MAPK (15) and it has initially been 
shown that p38 is activated by LPS stimulation of monocytes (16, 17). Subsequently, p38 has 
been shown to play a critcal role for the regulation of proinflammatory genes such as cytokines 
(18) and cyclooxygenase-2 (Cox-2)(19). Because targeted deletion of the p38α gene in mice 
causes embryonic lethality (20), p38α appears to be of major physiological significance among 
the known p38 isoforms. Although numerous studies have demonstrated that activation of p38 
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mediates HO-1 induction by a host of stimuli (2, 3, 9), an inhibitory role of p38 on HO-1 gene 
expression has previously been reported (21, 22). Thus, it was the primary goal of the present 
study to evaluate the role of p38 for HO-1 gene expression in further detail.  
In the current report, it is shown that small molecule inhibitors of p38 induced HO-1 expression 
in monocytic cells and that basal HO-1 gene expression was constitutively high in murine 
embryonic fibroblasts (MEF) from p38α-/- mice. Moreover, p38 inhibition-dependent HO-1 gene 
induction was regulated via the transcription factor (TF) NF-E2-related factor-2 (Nrf2), which is 
a central regulator of the cellular stress response. Activation of ERK and reactive oxygen species 
(ROS) were involved in this up-regulation of HO-1 gene expression. 
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MATERIALS AND METHODS   
Materials 
Dulbecco’s modified Eagle’s medium and RPMI 1640 were obtained from PAA Laboratories 
(Pasching, Germany), FCS was from Biochrom KG (Berlin, Germany), Ficoll-Paque was from 
Pharmacia (Freiburg, Germany), CD14+ immunomagnetic microbeads were from Miltenyi 
Biotech (Bergisch-Gladbach, Germany) and polyvinylidene diflouride membranes were from 
Millipore (Bedford, MA). All other chemicals were purchased from Sigma-Aldrich and Roche 
Applied Science, unless otherwise indicated. 
Cell isolation and culture  
RAW264.7 cells were from American Type Culture Collection (Manassas, VA), MEF from 
p38α-/- mice  were from Dr. Angel R. Nebreda (Spanish National Cancer Center, Madrid, Spain) 
(23), MEF from Nrf2-/- mice were from Dr. Larry Higgins (University of Dundee, UK)(24) and 
were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, 
100 U/ml penicillin and 100 µg/ml streptomycin. Human PBMC were isolated and maintained in 
culture as described previously (25). All cell cultures were kept under air/CO2 (19:1) at 100% 
humidity. Treatment of cells with PMA (0.5 µM), LPS (E. coli 0111:B4; 1 µg/ml), inhibitors of 
p38 MAPK (SB202190 and SB 203580, Calbiochem), ERK (PD 98059, Calbiochem) or JNK 
(SP 600125, Calbiochem) was performed with serum-free medium. N-acetylcysteine (NAC) was 
added to the culture medium 30 min prior to treatment with PMA, as indicated.  
Subcellular fractionation 
p38α-/- and p38α+/+ MEF were cultured overnight in complete media and were washed twice in 
ice-cold PBS. Thereafter, cells were incubated in 200 µl of ice-cold homogenizing buffer 
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containing 250 mM sucrose pH 7.4, 5 mM MOPS pH 7.4, 0.1% ethanol, 1 mM EDTA, 0.2 mM 
DTT, 1 mM 6-aminocaproic acid and protease inhibitor cocktail for 15 min. Cells were scraped 
from the dishes, dounce-homogenized with 50 strokes and centrifuged at 2500 x g for 20 min at 
4°C to separate nuclei from cytosol. The   supernatant was collected as cytosolic fraction, and the 
pelleted nuclear fraction was washed twice in homogenizing buffer and incubated in 100 µl of 
extraction buffer containing 25% glycerol, 20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, pH 
8.0, 1 mM EGTA, 1 mM DTT and protease inhibitor cocktails. Samples were rocked at 4°C for 
20 min and centrifuged at 12,000 x g for 10 min. This fraction was collected as nuclear extract 
(NE). All fractions were brought to equal volumes and protein content was determined for the 
cytosol and nuclear extract fractions.  
Western blot analysis  
Cells were washed with 0.9% NaCl and thereafter lysis and protein quantitation was essentially 
performed as described previously (25). 50 µg of total protein was separated on a 12% SDS-
polyacrylamide gel and was blotted onto polyvinylidene difluoride membranes. Membranes were 
blocked with Tris-buffered saline containing 5% skim-milk or 5% BSA, 50 mM Tris/HCl (pH 
7.6), 150 mM NaCl and 0.1% Tween 20 for 1 h at room temperature. The primary antibodies 
against HO-1 (Stressgen, Victoria, BC, Canada), peroxiredoxin 1 (26), Cox-2 (Alexis 
Biochemicals, Grünberg, Germany) and GAPDH (Hytest, Turku, Finland) were used at 1:1000 
dilutions. The primary antibodies against Nrf2 and lamin B1 were from (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA) and were used at 1:2000 dilutions. The primary antibody 
against Bach1 was a gift from Dr. Kazuhiko Igarashi (Tohoku University School of Medicine, 
Sendai, Japan) and was used at 1:1000 dilution (27). Primary antibodies for detection of 
phosphorylated and total MAPK were from Cell Signaling and were applied at the 
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concentrations recommended by the manufacturer, respectively. Secondary antibodies were goat 
anti-rabbit IgG horseradish peroxidase and anti-mouse IgG horseradish peroxidase (DPC 
Biermann, Bad Nauheim, Germany) and were used at 1:20,000 and 1:100,000, respectively. The 
ECL chemiluminescent detection system (Amersham) was used for detection according to the 
manufacturer's instructions. The chemiluminescent autoradiographic signals were visualized and 
quantitated with the Fluorchem FC2 gel documentation system.  
Plasmid constructs  
The luciferase reporter gene constructs pHO-4045-luc was a gift from Dr. Mark A. Perella 
(Harvard Medical School, Boston, Massachusetts)(28), pE2-luc was a gift from Dr. Jawed Alam 
(Alton Ochsner Medical Center, New Orleans, LS)(29). Plasmid pFA-CHOP with the 
transactivation domain of the TF CHOP, plasmid pFA-Elk with the transactivation domain of the 
TF Elk each fused with the DNA-binding domain of yeast Gal4 and the empty control vector 
pFC2-dbd were purchased from Stratagene. The plasmid pAP-1-luc with three AP-1 repeats in 
front of a minimal fos promoter was a gift from Dr. Craig A. Hauser (The Burnham Institute, La 
Jolla, CA)(30). 
Transfection and luciferase assay  
After growth for 24 h, transfection of plasmid DNA into RAW264.7 cells and MEF was 
performed by using FuGENE (Roche Applied Science) as described previously (25). Unless 
otherwise indicated, cells were transfected with 0.5 to 1 µg of the reporter plasmid, and in 
cotransfection experiments with 0.1 to 1 µg of the indicated expression vectors. Transfection 
efficiency was controlled using 0.1 µg of Renilla luciferase expression vector pRL-SV40 
(Promega) as described previously (25). Cells were lysed with luciferase lysis reagent 
(Promega), and luciferase activity was determined with the commercial Dual Luciferase reporter 
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assay system (Promega) according to the manufacturer’s instructions. Cells were either harvested 
24 h after transfection or treated for another 18 h with the indicated reagents, respectively. 
Relative light units of Firefly luciferase activity were normalized with Renilla luciferase activity. 
Preparation of NE and EMSA 
NE were prepared as described previously (25). The sequences of the biotin-labeled 
oligonucleotides (MWG, Ebersberg, Germany) used for the EMSA are as follows: E2, (5'-
GTGCCTTTTCTGCTGAGTCAAGGTCCGGGG-3'), E2mutant (E2mut), (5'-GTGCCTTTTCT- 
GCTTATTTAAGGTCCGGGG-3') and NF-κB consensus oligonucleotide with sequence (5'-
AGTTGAGGGGACTTTCCCAGGC-3') with respective oligonucleotides of the non-coding 
strand. For competition assays an excess of unlabeled oligonucleotide was added, as indicated. 
After preincubation for 10 min at room temperature, the biotin-labeled probe was added and 
incubation was continued for another 20 min. For supershift analysis 1 to 2 μl of antibody either 
directed against Nrf2 (Santa Cruz Biotechnology) or anti-sera raised against mouse NB1 protein 
(from Dr. Stroncek, NIH, Bethesda, NY), were added to the EMSA reaction, as indicated. The 
reaction mixture was loaded on a 6% native polyacrylamide gel in 0.5% TBE and was blotted 
onto nylon membranes (Pierce). After UV-cross-linking the LightShift Chemiluminescent 
EMSA kit (Pierce) was used to detect interaction between biotin end-labeled DNA and protein 
with a streptavidin-horseradish peroxidase conjugate and the chemiluminescent substrate. 
Measurement of ROS  
Intracellular generation of ROS was detected with dihydroethidium (DHE) dye (Invitrogen). The 
fluorescent byproduct ethidium, which is produced after DHE cleavage by ROS, was detected 
with a flow cytometer. Cells were incubated with or without SB 202190 (10 µM) for 1 h, after 
which they were washed and further incubated for 20 min with 5 µM DHE. Cells were then 
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washed with PBS and the levels of ROS were determined with a FACScalibur flow cytometer. 
DHE-detectable superoxide anion (FL2-H) fluorescent signals were displayed as histograms. 
Ratios of signals versus control data were calculated by mean fluorescence intensity.  
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RESULTS 
Up-regulation of HO-1 gene expression via pharmacological inhibition and genetic 
deficiency of p38 MAPK  
In agreement with earlier work the phorbol ester PMA and the proinflammatory mediator LPS 
induced HO-1 (25, 31) and Cox-2 (32) gene expression in cell cultures of RAW264.7 monocytes 
(Figure 1A). Previous reports have shown that p38 MAPK contributes to the PMA-dependent 
induction of these two genes (25, 31-33). Although pretreatment of RAW264.7 cells with SB 
202190, which pharmacologically blocks p38α and p38β MAPK activity, reduced PMA-
dependent induction of HO-1 and Cox-2, treatment with this compound alone markedly induced 
HO-1, but not Cox-2, gene expression (Figure 1B). This unexpected observation was confirmed 
in a second series of experiments, in which HO-1 gene expression in RAW264.7 cells was time-
dependently up-regulated by SB 202190 and by a second p38α inhibitor, SB 203580 (Figure 
1C). To specify these results we investigated PMA-dependent regulation of HO-1 and Cox-2 
gene expression in cell cultures of MEF, that were genetically deficient for p38α (p38α-/- MEF) 
in comparison to that in wild-type MEF (p38α+/+ MEF). While PMA induced HO-1 and Cox-2 
expression in p38α+/+ MEF, it had only minor effects in p38α-/- MEF. Importantly, the basal level 
of HO-1 protein expression was significantly higher in p38α-/- MEF, if compared to that in 
p38α+/+ MEF (Figure 1D). In contrast, Cox-2 protein was hardly detectable in both p38α-/- and 
p38α+/+ MEF (Figure 1D). For a comparison, we determined HO-1 gene expression in cell 
cultures of human PBMC. HO-1 gene expression was augmented in human PBMC in the 
presence of the p38 inhibitor SB 203580 (Figure 1E).  
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The data indicate that pharmacological inhibition and genetic deficiency of p38α causes an 
increased HO-1 gene expression. 
Constitutive activation of p38 MAPK in RAW264.7 cells 
It is generally accepted that numerous stimuli can activate p38 MAPK (14). Since 
pharmacological inhibition of p38 in RAW264.7 cells has an effect on HO-1 gene expression, 
which is similar to that in p38-/- MEF (Figure 1), we examined p38 activity in untreated 
RAW264.7 cells. Interestingly, p38 phosphorylation could be detected under basal conditions 
and exposure to SB 202190 and SB 203580 markedly attenuated this phosphorylation (Figure 
2A). In addition, we verified the functionality of p38 in RAW264.7 cells by a cotransfection 
assay, in which a luciferase reporter construct with five binding sites for the yeast transcription 
factor Gal4 was used together with a construct allowing expression of a fusion protein consisting 
of the Gal4 DNA-binding domain and the transactivation domain of the TF CHOP (pFA-CHOP). 
Transactivation of CHOP is regulated by p38-dependent phosphorylation of regulatory serine 
residues within the CHOP transactivation domain (34). Similar to the data on p38 
phosphorylation in Figure 2A, high luciferase activity of pFA-CHOP was observed under basal 
conditions and exposure of RAW264.7 cells to SB 202190 and SB 203580 reduced reporter gene 
activity (Figure 2B). When p38-/- and p38+/+ MEF were transfected with pFA-CHOP, luciferase 
activity was low in p38-/- MEF, whereas it was significantly higher in p38+/+ cells. Here, reporter 
gene activity was inhibited by SB 202190 and SB 203580 (Figure 2C). The data demonstrate that 
p38 MAPK activity is constitutively high in RAW264.7 monocytic cells. 
HO-1 gene expression is not affected by inhibitors of JNK and ERK  
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To investigate whether inhibition of MAPK other than p38 would affect HO-1 gene expression, 
RAW264.7 cells were treated with specific inhibitors for JNK, SP 600125, and ERK, PD 98059, 
respectively. For a comparison cells were also treated with PMA. In contrast to p38 inhibitors, 
treatment with these inhibitors did not induce HO-1 gene expression (Figure 3) indicating that 
inhibition of JNK and ERK did not affect basal HO-1 gene expression in RAW264.7 cells. 
Genetic deficiency and pharmacological inhibition of p38 induces HO-1 gene promoter 
activity 
Nrf2, a member of the cap’n’collar family of basic leucine zipper proteins (35, 36), plays a major 
regulatory role for the stress-dependent transcriptional induction of HO-1 gene expression (37, 
38). Although p38 has been shown to be involved in Nrf2 activation, the exact regulatory role of 
p38 for Nrf2 activation is not well understood (39). To further investigate this pathway, we 
determined the regulation of luciferase reporter gene constructs pHO-4045-luc and pE2-luc, both 
of which carry the proximal (E1) and distal (E2) enhancer sequences of the mouse HO-1 
promoter (37). Both enhancer sequences contain multiple copies of StRE sites that are targeted 
by Nrf2 (2). For a comparison, we also transfected p38-/- and p38+/+ MEF with the pAP-1-luc 
construct, which carries three copies of the consensus recognition sequence of AP-1 (30). Basal 
luciferase activity of the reporter gene constructs pHO-4045-luc and pE2-luc, but not that of 
pAP-1-luc, was markedly higher in p38-/- MEF as compared to that in p38+/+ MEF (Figure 4A). 
Furthermore, treatment with SB 202190 up-regulated reporter gene activity of these constructs in 
RAW264.7 cells (Figure 4B). Luciferase activity of the pE2-luc construct was slightly higher in 
comparison to that of pHO-4045-luc in p38-/- MEF and in RAW264.7 cells (Figure 4). Taken 
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together, the data suggest that an Nrf2-dependent transcriptional mechanism is involved in HO-1 
gene activation via inhibition of p38. 
p38 contributes to nuclear localization of Nrf2 
Nrf2 regulates HO-1 gene expression via shuttling between the nucleus and cytoplasm in 
response to various stress-stimuli (35, 36). To further investigate whether p38 may regulate Nrf2 
localization, nuclear and cytoplasmic Nrf2 levels were determined in p38-/- and p38+/+ MEF. For 
a comparison, we also determined protein levels of Bach1, which is a counter-regulator of Nrf2 
and represses HO-1 gene expression (27). Nrf2 levels were higher in nuclear fractions of p38-/- 
MEF as compared to those in p38+/+ MEF. By contrast, no appreciable difference of Nrf2 levels 
was observed in cytoplasmic fractions (Figure 5, upper panel). Remarkably, cytosolic and 
nuclear levels of Bach1 were inverse to those of Nrf2 with higher Bach1 levels in cytoplasmic 
fractions of p38-/- MEF as compared to those in p38+/+ MEF.  
Inhibitors of p38 do not up-regulate HO-1 gene expression in Nrf2-/- MEF 
To further examine the role of p38 on Nrf2-dependent HO-1 gene regulation, Nrf2-/- and Nrf2+/+ 
MEF were treated with small molecule inhibitors of p38 and PMA. Treatment with SB 202190 
and SB 203580 significantly induced HO-1 gene expression in Nrf2+/+ MEF, but not in Nrf2-/- 
MEF (Figure 6A) and luciferase activity of transfected pHO-4045-luc and pE2-luc constructs 
was markedly higher in Nrf2+/+ MEF as compared to that in Nrf2-/- MEF (Figure 6B). 
Furthermore, treatment with SB 202190 up-regulated luciferase activity of two HO-1 gene 
constructs to a magnitude similar to that by PMA in Nrf2+/+ MEF, but not in Nrf2-/- MEF (Figure 
6B). In contrast, reporter gene activity of the pAP-1-luc construct was not affected by p38 
inhibitors (Figure 6B). Taken together, the data suggest that inhibition of p38 induces HO-1 gene 
expression in a Nrf2-dependent manner. 
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Induction of DNA-binding of Nrf2 in response to p38 inhibitors 
We also examined the binding activity of nuclear proteins from RAW264.7 cells to a biotin-
labeled E2 oligonucleotide with a StRE site of the mouse HO-1 gene promoter (37) in EMSA 
studies. After treatment with p38 inhibitors NE from RAW264.7 cells formed an inducible 
DNA-protein complex, which was similar to that observed in response to treatment with LPS 
(Figure 7A). The intensity of the DNA-protein complex from SB 202190-treated cells was 
decreased by an unlabeled E2 oligonucleotide, but not by an oligonucleotide with a mutation of 
the StRE site (E2 mut, Figure 7B) or a NF-κB oligonucleotide (Figure 7C). Incubation of the 
DNA-protein binding reaction with an ab against Nrf2 reduced the intensity of DNA-protein 
complex formation (Figure 7C). Taken together, the data indicate that the StRE site of the E2 
region is a nuclear binding site for Nrf2 and may be involved in the regulation of p38 dependent 
induction of HO-1 gene expression. 
Role of ERK for HO-1 gene activation via p38 inhibition 
ERK is involved in HO-1 gene induction by numerous stimuli (3, 9). Since p38 MAPK has 
previously been shown to have a negative regulatory effect on ERK activity (23), we 
investigated the effect of p38 MAPK inhibition on ERK phosphorylation and its potential effect 
on HO-1 gene expression in p38-/- and p38+/+ MEF. As demonstrated in Figure 8A, ERK was 
strongly phosphorylated in p38-/- MEF, but not in p38+/+ MEF. Serum starvation did not affect 
ERK phosphorylation in either cell type. Treatment with a specific inhibitor of ERK attenuated 
the increased levels of HO-1 in p38-/- MEF suggesting a regulatory cross-talk of these protein 
kinases for HO-1 gene regulation (Figure 8B). Subsequently, we determined the effect of p38 
inhibition on ERK phosphorylation in RAW264.7 cells. Treatment with p38 inhibitors induced 
ERK phosphorylation in these cells similar to that by the known ERK activator PMA (Figure 
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8C). Finally, the reporter gene construct pFA-Elk which is specifically regulated via ERK, was 
markedly induced by p38 inhibitors in RAW264.7 cells. As a control, treatment with PMA 
strongly induced luciferase activity of pFA-Elk (Figure 8D). Taken together, the data suggests 
that genetic deficiency or pharmacological inhibition of p38 activates ERK and may be involved 
in the induction of HO-1 gene expression. 
Genetic deficiency and pharmacological inhibition of p38 MAPK causes increased 
accumulation of cellular ROS 
Genetic deficiency of p38α MAPK has previously been shown to lead to an increased 
accumulation of ROS (40). Accordingly, p38-/- MEF exhibited a two-fold increase of 
intracellular ROS levels in comparison to p38+/+ MEF (Figure 9A, B). Moreover, treatment of 
p38+/+ MEF with SB 202190 augmented intracellular levels of ROS (Figure 9A, B) and the 
generation of ROS was also enhanced in SB 202190-treated RAW264.7 cells (data not shown). 
ROS have previously been demonstrated to up-regulate HO-1 gene expression in 
immunologically active cells and have been proposed to function as putative second messengers 
for the induction of this gene (2, 9, 25, 41). To investigate whether ROS would directly affect 
HO-1 gene expression, we treated p38+/+ and p38-/- MEF with the antioxidant NAC. NAC 
reduced basal HO-1 expression in p38-/- MEF, but had no effect in p38+/+ MEF (Figure 9C). 
Similarly, treatment with NAC markedly attenuated HO-1 gene expression in RAW264.7 cells. 
In line, induction of HO-1 expression by PMA, a known inducer of ROS production in 
monocytes (42) was abrogated by NAC (Figure 9D). The data suggest that genetic deficiency 
and pharmacological inhibition of p38 increases the intracellular generation of ROS, which are 
involved in the up-regulation of HO-1 gene expression. 
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DISCUSSION                          
The enzyme HO-1, which catalyzes the first and rate-limiting step of heme degradation, has 
attracted major attention in recent years, because its products CO and biliverdin have potent 
antioxidant and anti-inflammatory functions. Activation of the p38 MAPK pathway has 
previously been shown to be involved in HO-1 induction by a wide variety of stimuli. In the 
present study it is demonstrated that: 1) pharmacological inhibition of p38 in monocytic cells and 
genetic deficiency of p38α in MEF cause an up-regulation of HO-1 gene expression; 2) the 
increased HO-1 expression by inhibition of p38 is mediated via the TF Nrf2; 3) activation of 
ERK and ROS are involved in this HO-1 gene regulation. 
Up-regulation of HO-1 gene expression by pharmacological inhibition and genetic 
deficiency of p38 MAPK is transcriptionally regulated via Nrf2 
Inhibition of p38 MAPK by small molecule inhibitors in monocytic cells and genetic deficiency 
of p38α in MEF led to increased gene expression of HO-1, but not that of Cox-2 (Figure 1). It is 
remarkable that HO-1 levels were constitutively high in p38-/- MEF, because basal HO-1 
expression is known to be barely detectable in most cells and tissues under non-stimulated 
conditions (2, 3). The present findings are in keeping with a recent report demonstrating that 
basal expression of several genes was increased without external stress stimuli in immortalized 
p38α-/- cardiomyocytes (43). Up-regulation of HO-1 gene expression by inhibition of p38, 
however, was unexpected, because this protein kinase is considered to play a major role for 
mediating HO-1 induction by multiple stress stimuli (2, 3, 9). Thus, the present observations 
suggest that p38α may have a dual function for HO-1 gene regulation. 
p38 MAPK modulates gene expression via transcriptional and post-transcriptional mechanisms 
(44). The present study demonstrates that HO-1 gene expression by inhibition or genetic 
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deficiency of p38 occurs on the transcriptional level via the TF Nrf2 (Figures 4-7), which is a 
central regulator of the cellular oxidative stress response (35, 36) and plays a major role for the 
induction of HO-1 (3, 37, 38).  Nrf2 targets to StRE, several of which are localized in the 5'-
flanking sequence of the HO-1 gene promoter (3). StRE, also referred to as antioxidant response 
elements or electrophile response elements, have been identified in a large number of phase II 
detoxifying enzymes and antioxidant stress proteins (39). An inhibitory role of p38 on Nrf2-
mediated gene regulation is also supported by the finding that expression of peroxiredoxin 1, 
which is coordinately regulated with HO-1 (26) via an Nrf2-dependent mechanism (38), was 
induced by inhibition of p38 (data not shown). Similar to the findings of our present report, 
chemical blockage of p38 has previously been shown to enhance StRE-mediated induction of 
phase II detoxifying enzymes (21) and the sulforaphane-dependent HO-1 activation via Nrf2 in 
human hepatoma HepG2 cells (22). Our observations also implicate that Bach1, which is a 
counter-regulator of Nrf2 and a repressor of HO-1 gene expression (27), may be involved in the 
transcriptional regulation of HO-1 via p38 MAPK (Figure 5). Finally, we cannot exclude the 
possibility that Nrf2-independent regulatory mechanisms are involved in the up-regulation of 
HO-1 gene expression via p38 MAPK. 
Regulatory pathways of increased HO-1 gene expression by pharmacological inhibition 
and genetic deficiency of p38 MAPK 
In accordance with an earlier report (23), the present study demonstrates that genetic deficiency 
of p38α caused an increased ERK activity (Figure 8). Since HO-1 gene expression in p38-/- MEF 
was blocked by the ERK inhibitor PD 98059, it is conceivable that the MAPK p38 and ERK 
have opposite regulatory roles for governing HO-1 gene expression. This assumption would 
correspond with a previous study, in which pharmacological inhibition of p38 induced low 
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density lipoprotein receptor expression via activation of ERK in HepG2 cells (45). 
Independently, others have demonstrated that blockage of p38 increased LPS-dependent 
inducible NO synthase gene expression and NO production via activation of JNK in 
macrophages (46). Considerable variations have been reported for the regulatory role of various 
MAPK on HO-1 gene expression. Elbirt et al., have reported that activation of ERK and p38 
MAPK were required for the arsenite-dependent induction of HO-1 gene expression in avian 
hepatocytes (47). By contrast, both JNK and p38 MAPK were necessary for HO-1 induction by 
this compound in rat hepatocytes (48). Thus, a complex network of MAPK appears to modulate 
HO-1 gene expression in a stimulus-, cell- and species-specific manner.  
p38 could be involved in the sensing of cellular oxidative stress, because transformed p38α- 
deficient cells have been reported to accumulate much larger amounts of ROS than wild type 
cells (40). This observation corresponds with our present findings (Figure 9) and ROS are likely 
mediating ERK activation in cells lacking p38α (23). The latter assumption would be supported 
by recent reports, which demonstrated that ROS mediate a sustained activity of ERK in human 
hepatoma cells (49) and in a model of cerebral ischemia (50). Accordingly, treatment with the 
antioxidant NAC attenuated the p38-dependent increase of HO-1 gene expression (Figure 9).  
Physiological significance of HO-1 up-regulation by pharmacological inhibition and genetic 
deficiency of p38 MAPK 
Since HO-1 has potent anti-apoptotic functions (3), the increase of HO-1 expression levels in 
p38α-/- MEF corresponds with the observation that p38α deficiency makes these cells less 
sensitive to apoptosis via up-regulation of anti-apoptotic genes (23). It is also important to note 
that anti-apoptotic effects of HO-1 have recently been associated with the degradation of p38α in 
endothelial cells (51). Taken together these findings may suggest an intimate interaction of HO-1 
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and p38α regulation. HO-1 has attracted major attention in recent years, because it has 
antioxidant cytoprotective and anti-inflammatory and immunomodulatory functions (3, 9-13). In 
particular, the anti-inflammatory role of HO-1 has initially been shown in HO-1 deficient mice 
that exhibited a proinflammatory phenotype and were highly sensitive to LPS-mediated toxicity. 
Remarkably, these observations in HO-1-/- mice have essentially been confirmed in a human case 
of HO-1 genetic deficiency (6). More recently, it has been demonstrated that loss of HO-1 
activity in APC is associated with impaired suppressor function of regulatory T cells (8).  
In summary, the present study demonstrates that the HO-1 gene is activated via pharmacological 
inhibition and genetic deficiency of p38 MAPK. These findings not only give new insights into 
the regulatory mechanisms of HO-1 gene expression, but also show the complex regulatory 
network that modulates the inflammatory response in monocytic cells. These findings may 
ultimately help to develop novel therapeutic approaches for the treatment of inflammatory 
diseases. 
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FIGURE LEGENDS 
Figure 1: Pharmacological inhibition in monocytic cells and genetic deficiency of p38 up-
regulate HO-1 gene expression  
RAW264.7, p38+/+, p38-/- MEF and human (hu) PBMC were cultured as described under 
Materials and Methods. (A) RAW264.7 cells were treated with or without PMA (0.5 µM) or 
LPS (1 µg / ml) for 18 h. (B) RAW264.7 cells were pretreated with SB 202190 (7.5 and 12 µM) 
for 30 min, after which treatment was continued with or without PMA (0.5 µM) for another 6 h, 
as indicated. (C) RAW264.7 cells were treated with SB 202190 (10 µM), SB 203580 (20 µM) or 
control medium for the times indicated. (D) p38+/+ and p38-/- MEF were treated with PMA (0.5 
µM) or control medium for 18 h, as indicated. (E) Human PBMC were treated with or without 
SB 203580 (20 µM) and PMA (0.5 µM) for 6 h. Total protein (50 µg) was subjected to Western 
blot analysis and sequentially probed with antibodies against HO-1, Cox-2 and GAPDH (A, B 
and D), or HO-1 and GAPDH (C and E), as indicated. Autoradiograms from representative 
experiments are shown in A-E, respectively. Autoradiographic signals were visualized and 
quantified using the Fluorchem FC2 gel documentation system. (D) Numbers represent the 
protein expression levels relative to p38+/+ MEF normalized to GAPDH from at least three 
independent experiments ± SEM. (B and E) Values ± SEM represent the -fold induction of HO-1 
normalized to GAPDH from three independent experiments. Statistics, Student’s t test for paired 
values: *, significant differences treatment versus control; **, p38+/+ control versus p38-/- control, 
p ≤ 0.05. RAW, RAW264.7 cells. 
Figure 2:  Activity of p38 MAPK in RAW264.7 and MEF cell cultures 
(A) RAW264.7 cells were treated with or without SB 202190 and SB 203580 for the times 
indicated. Western blot analysis was performed as described in Figure 1 and probed sequentially 
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with antibodies against phospho-specific p38 and total p38 MAPK. Similar results were obtained 
in three independent experiments and a representative autoradiogram is shown. (B, C) 
RAW264.7 cells and p38+/+, p38-/- MEF were cotransfected with luciferase reporter gene 
construct pGal4-luc, pFC2-dbd, and pFA-CHOP, as indicated. 24 h after transfection cells were 
treated with SB 202190 (10 µM) and SB 203580 (20 µM) for 18 h. Cell extracts were assayed 
for luciferase activity, and the -fold induction relative to the control was determined. Values are 
means ± SEM from at least three independent experiments with duplicates of each point. 
Statistics, Student's t test for paired values: *, significant differences pFC2-dbd versus pFA-
CHOP; **, treatment versus control, p < 0.05.  
Figure 3: Effect of JNK and ERK inhibitors on HO-1 gene expression 
RAW264.7 cells were treated with or without SB 202190, SP 600125, PD 98059 and PMA at the 
indicated concentrations (µM). Western blot analysis and quantitation was performed as 
described in Figure 1. Values ± SEM represent the -fold induction of HO-1 normalized to 
GAPDH from three independent experiments. Statistics, Student’s t test for paired values: *, 
significant differences treatment versus control, p < 0.05. 
Figure 4:  Role of p38 MAPK for the regulation of HO-1 promoter activity  
(A) p38-/- and p38+/+ MEF were transfected with the indicated reporter gene constructs. 24 h after 
transfection cell extracts were assayed for luciferase activity. The -fold induction relative to 
p38+/+ was determined. Values are means ± SEM from at least three independent experiments 
with duplicates of each point. Student’s t test for paired values: *, significant differences p38+/+ 
versus p38-/-, p < 0.05. (B) RAW264.7 cells were transfected with the indicated reporter gene 
constructs. 24 h after transfection cells were treated with or without SB 202190 (10 µM) for 18 
h. Cell extracts were assayed for luciferase activity, and the -fold induction relative to the control 
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was determined. Values are means ± SEM from at least three independent experiments with 
duplicates of each point. Statistics, Student's t test for paired values: *, significant differences 
treatment versus control, p < 0.05.  
Figure 5: Subcellular localization of Nrf2 and Bach1 in p38-/- and p38+/+ MEF 
Cytosolic and nuclear fractions from cell cultures of p38-/- and p38+/+ MEF were separated as 
described under Materials and Methods. Western blotting and quantitation was performed as 
described in Figure 1. Similar results were obtained in three independent experiments and 
representative autoradiograms are shown. Values ± SEM represent protein levels of Nrf2 and 
Bach1 in cytosolic and nuclear fractions relative to p38+/+ MEF normalized to GAPDH from 
three independent experiments and purity of nuclear fraction was controlled with a lamin B 
antibody. Statistics, Student’s t test for paired values: *, significant differences p38+/+ versus p38-
/-, p < 0.05. C, cytosolic fraction; N, nuclear fraction. 
Figure 6: HO-1 gene regulation in Nrf2-/- and Nrf2+/+ MEF 
(A) Nrf2-/- and Nrf2+/+ MEF were cultured as described under Materials and Methods, and were 
treated with or without SB 202190 (10 µM) , SB 203580 (20 µM) and PMA (0.5 µM) for 18 h. 
Western blotting and quantitation was performed as described in Figure 1. Similar results were 
obtained in three independent experiments and a representative autoradiogram is shown. Values 
± SEM represent the -fold induction of HO-1 normalized to GAPDH from three independent 
experiments. Statistics, Student’s t test for paired values: *, significant differences treatment 
versus control, p < 0.05. (B)  Nrf2-/- and Nrf2+/+ MEF were transfected with the indicated 
reporter gene constructs. 24 h after transfection cells were treated with or without SB 202190 (10 
µM) and PMA (0.5 µM) for 18 h. Cell extracts were assayed for luciferase activity, and the 
luciferase activity relative to Nrf2-/- was determined. Values are means ± SEM from at least three 
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independent experiments with duplicates of each point. Statistics, Student's t test for paired 
values: *, significant differences treatment versus control; **, activity of pHO-4045 or pE2-luc 
in Nrf2-/- MEF versus Nrf2+/+ MEF, p < 0.05. 
Figure 7: Binding of nuclear proteins to a StRE oligonucleotide is induced by p38 
inhibitors 
(A) A biotin-labeled oligonucleotide with a StRE element of the distal enhancer sequence (E2) of 
the mouse HO-1 promoter was incubated with 7 μg of NE from control RAW264.7 cells or from 
cells treated with SB 202190, SB 203580 and LPS. (B) For competition analyses the biotin-
labeled E2 oligonucleotide was preincubated with 7 μg of NE from SB 202190 (10 μM) treated 
cells along with a 10-, 50- and 100-fold molar excess of unlabeled E2 oligonucleotide or a 100-
fold molar excess of E2 mut oligonucleotide, as indicated. (C) For super-shift analysis 1 or 2 µl 
of an antibody directed against Nrf2 was preincubated with NE from SB 202190 treated cells 
before the biotin-labeled E2 oligonucleotide was added. For a comparison, a 50-fold molar 
excess of unlabeled oligonucleotide with the consensus κB sequence, or 1 µl of anti-sera raised 
against mouse NB-1 protein was added.  DNA-protein complexes were separated by 
electrophoresis on a 6% native polyacrylamide gel. 
Figure 8: ERK activation is involved in p38-dependent HO-1 gene regulation 
(A) p38-/- and p38+/+ MEF were cultured with or without FCS and (B) p38-/- and p38+/+ MEF were 
treated with or without PD98059  for 6 h. (C) RAW 264.7 cells were treated with SB 202190 (10 
µM), SB 203580 (20 µM) and PMA (0.5 µM) or control media, as indicated. Western blot 
analysis was performed as described in Figure 1 and probed sequentially with antibodies (A, C) 
against phosphorylated ERK and total ERK, (B) HO-1 and GAPDH. Similar results were 
obtained in three independent experiments and representative autoradiograms are shown, 
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respectively. (D) RAW264.7 cells were cotransfected with luciferase reporter gene construct 
pGal4-luc, pFC2-dbd, and pFA-Elk. 24 h after transfection cells were treated with or without SB 
202190 (10 µM), SB 203580 (20 µM) and PMA (0.5 µM) for 18 h. Luciferase assay and 
quantitation was performed as described in Figure 2. Values are means ± SEM from at least three 
independent experiments with duplicates of each point. Statistics, Student's t test for paired 
values: *, significant differences treatment versus control, p < 0.05.  
Figure 9: Inhibition of p38 MAPK increases intracellular levels of ROS 
(A) p38-/- and p38+/+ MEF were cultured as described under Materials and Methods and p38+/+ 
MEF were treated with SB 202190 (10 µM) for 1 h. Cells were washed and incubated with DHE 
stain (5 µM) for 20 min and analyzed by flow cytometry. (B) Numbers indicate mean 
fluorescence intensity relative to p38+/+ MEF from at least three independent experiments ± 
SEM. Statistics, Student’s t test for paired values: *, significant differences treatment versus 
control; **, p38+/+ control versus p38-/- control, p < 0.05.  (C) p38-/- and p38+/+ MEF were treated 
with or without NAC for 6 h at the indicated concentrations (5 and 25 mM). (D) RAW264.7 cells 
were pretreated with NAC at the indicated concentrations (mM) for 30 min, after which 
treatment was continued for another 6 h with or without SB 202190 (10 µM) and PMA (0.5 µM). 
Western blot analysis and quantitation was performed as described in Figure 1. (C, D) Similar 
results were obtained in three independent experiments and representative autoradiograms are 
shown. (D) Values ± SEM represent the -fold induction of HO-1 normalized to GAPDH from 
three independent experiments. Statistics, Student’s t test for paired values: *, significant 
differences treatment versus control; **, treatment versus NAC + treatment, p < 0.05.  
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2. SUMMARY 
 Mononuclear phagocytes (monocytes, macrophages) play a pivotal role for the 
regulation of inflammation. An uncontrolled immunological response of activated 
mononuclear cells may cause irreversible tissue damage and chronic inflammatory 
disorders. Therefore, antioxidant and anti-inflammatory mechanisms of mononuclear 
cells are essential for the resolution of inflammation and restoration of immune 
homeostasis. Up-regulation of peroxiredoxin I (Prx I) and heme oxygenase-1 (HO-1) 
has been shown to have potent antioxidant and immunomodulatory properties. 
 This thesis integrates three original articles that demonstrate the signaling 
pathways involved in the regulation of the antioxidant genes Prx I and HO-1 by the 
prototypical monocyte activators phorbol myristate acetate (PMA) and 
lipopolysaccharide (LPS), in monocytic cells.  
 Prx I gene expression was up-regulated by PMA and was inhibited by 
simultaneous treatment with LPS in RAW264.7 monocytic cells. The repressive effect 
of LPS on Prx I gene activation by PMA was mediated via a newly identified κB site 
of the Prx I gene promoter. A ‘non-classical’ NF-κB pathway, that includes 
phosphorylation of the NF-κB subunit p65 at serine 276 and a non-receptor tyrosine 
kinase Bruton's tyrosine kinase, was involved in the regulation of LPS-dependent 
inhibition of Prx I gene activation by PMA (Paper I).  
 HO-1 gene expression was transcriptionally induced by PMA with a regulatory 
pattern different from that by LPS in RAW264.7 monocytic cells. PMA-dependent 
HO-1 gene activation was mediated via a newly defined κB element of the rat HO-1 
promoter that serves as a nuclear target of p65. An IκB kinase-2-independent atypical 
NF-κB pathway, which was mediated via activation of p38 MAPK and CK2, was 
involved in HO-1 gene regulation by PMA (Paper II).  
 An unexpected up-regulation of HO-1 gene expression was observed by 
pharmacological inhibition of p38 in monocytes and by genetic deficiency of p38α in 
mouse embryonic fibroblasts (MEFs). The inhibitory effect of p38 on HO-1 gene 
expression was mediated via a stress response element (StRE) of the mouse HO-1 
gene promoter that is a nuclear target of the transcription factor NF-E2-related     
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factor 2 (Nrf2). Activation of the ERK pathway and generation of reactive oxygen 
species (ROS) were involved in HO-1 gene activation by p38 inhibition (paper III).  
 Taken together, the thesis demonstrates the complex regulatory pathways that 
control the induction of Prx I and HO-1 gene expression in activated monocytic cells. 
Thus, further studies on the regulation of these two genes may help to develop novel 
therapeutic strategies for the treatment of inflammatory diseases. 
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3. Zusammenfassung  
Mononukleäre Phagozyten (Monozyten, Makrophagen) spielen eine bedeutende 
Rolle bei der Regulation von Entzündungsreaktionen. Eine unkontrollierte 
Immunantwort von aktivierten mononukleären Zellen kann irreversible 
Gewebeschäden und chronische Entzündungen hervorrufen. Antioxidative und anti-
inflammatorische Mechanismen von mononukleären Zellen spielen daher eine 
wesentliche Rolle bei der Rückbildung von Entzündungsreaktionen und die 
Wiederherstellung des immunologischen Gleichgewichtes. Es ist bekannt, dass die 
Heraufregulation von Peroxiredoxin (Prx) I und Häm Oxygenase (HO)-1 stark 
antoxidativ und immunmodulatorisch wirkt. 
Die vorliegende Arbeit fasst den Inhalt von drei Originalpublikationen 
zusammen, die Signalwege beschreiben, die an der Regulation der antioxidativ 
wirksamen Gene HO-1 und Prx I durch die prototypischen Monozytenaktivatoren 
Phorbol-Myrisat Acetat (PMA) und Lipopolysaccharid (LPS) beteiligt sind. 
Die Prx I Genexpression wurde durch PMA heraufreguliert und wurde durch die 
gleichzeitige Behandlung mit LPS in RAW264.7 Monozyten gehemmt. Der 
hemmende Effekt von LPS auf die PMA-abhängige Prx I Genaktivierung wurde über 
ein neu identifiziertes κB Element im Prx I Genpromotor vermittelt. Ein nicht-
klassischer NF-κB Weg, der über Phosphorylierung der NF-κB Untereinheit p65 am 
Serinrest 276 und die Rezeptor-unabhängige Tyrosinkinase Bruton’s Tyrosinkinase, 
vermittelt wurde, war für die LPS-abhängige Hemmung der Prx I Induktion durch 
PMA verantwortlich (Arbeit I). 
Die HO-1 wurde in RAW264.7 Monozyten transkriptional durch PMA mit einem 
Genexpressionsmuster induziert, das sich von dem durch LPS hervorgerufenen 
Expressionsmuster unterschied. Die PMA-abhängige HO-1 Induktion wurde durch 
ein neu identifiziertes κB Element des Ratten HO-1 Genpromotors vermittelt, das als 
nukleäres Ziel für p65 diente. Ein IκB Kinase 2-unabhängiger atypischer NF-κB 
Weg, der über die Aktivierung von p38 MAPK und CK2 vermittelt wurde, war an 
dieser HO-1 Regulation durch PMA beteiligt (Arbeit II). 
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Eine unerwartete Heraufregulation der HO-1 Genexpression konnte durch 
pharmakologische Hemmung von p38 in Monozyten und bei genetischer Defizienz 
von p38α in embryonalen Fibroblasten der Maus (MEFs) beobachtet werden. Der 
hemmende Effekt von p38 auf die HO-1 Genexpression wurde über ein Stress-
abhängiges Element (StRE) innerhalb des Maus HO-1 Promotors vermittelt, das als 
nukleäres Ziel für den Transkriptionsfaktor NF E2-related factor 2 (Nrf2) diente. Die 
Aktivierung des ERK Signalweges und die Entstehung von reaktiven 
Sauerstoffspezies (ROS) spielten dabei eine regulatorische Rolle (Arbeit III).  
Zusammenfassend zeigt die vorliegende Arbeit die komplexen regulatorischen 
Signalwege, die die Induktion der Prx I und HO-1 Genexpression in Monozyten 
vermitteln. Ein besseres Verständnis der Regulation dieser beiden Gene könnte bei 
der Entwicklung neuer therapeutischer Strategien zur Behandlung entzündlicher 
Krankheiten helfen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
23 
 
4. References 
Abbas K, Breton J and Drapier JC. (2008): The interplay between nitric oxide and 
peroxiredoxins. Immunobiology 213: 815–822. 
Alam J and Cook JL. (2007). How many transcription factors does it take to turn on 
the heme oxygenase-1 gene? Am. J. Respir. Cell Mol. Biol. 36: 166-174 
Beaman LV and Beaman BL. (1984): The role of oxygen and its derivatives in 
microbial pathogenesis and host defense. Ann. Rev. Microbiol. 38:27-48 
Chen LF and Greene WC. (2004): Shaping the nuclear action of NF-κB. Nat.Rev. 
Mol. Cell Biol. 5: 392–401. 
Choi AMK and Alam J. (1996): Heme oxygenase-1: Function, regulation and 
implication of a novel stress-inducible protein in oxidant-induced lung injury. 
Am. J. Respir. Cell Mol. Biol. 15: 9–19. 
Datta R, Yoshinaga K, Kaneki M, Pandey P and Kufe D. (2000): Phorbol ester-
induced generation of reactive oxygen species is protein kinase c beta-dependent 
and required for SAPK activation. J. Biol. Chem. 275: 41000-41003. 
Dolado IA, Swat N, Ajenjo G, De Vita, Cuadrado A and Nebreda AR. (2007): 
p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. 
Cancer Cell 11: 191-205. 
Doyle SL, Jefferies CA and O'Neill LA. (2005): Bruton's tyrosine kinase is involved 
in p65-mediated transactivation and phosphorylation of p65 on serine 536 during 
NFkappaB activation by lipopolysaccharide. J. Biol.Chem. 280:23496–23501. 
Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N,  Jaruga P, 
Dizdaroglu M and Prochownik EV. (2005): Regulation of reactive oxygen 
species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 
24:8038–8050. 
Elbirt KK, Whitmarsh AJ, Davis RJ and Bonkovsky HL. (1998): Mechanism of 
sodium arsenite-mediated induction of heme oxygenase-1 in hepatoma cells. 
Role of mitogen-activated protein kinases. J. Biol. Chem. 273: 8922-8931 
Exner M, Minar E, Oswald W and Schillinger M. (2004): The role of heme 
oxygenase-1 promoter polymorphisms in human disease. Free Radic. Biol. Med. 
37:1097–1104. 
References 
 
24 
 
Ferrándiz ML and Devesa I. (2008): Inducers of heme oxygenase-1. Curr. Pharm. 
Des. 4:473-86. 
Hayden MS and Ghosh S. (2004): Signaling to NF-kappaB. Genes Dev. 18:2195–
2224. 
Hess A, Wijayanti N, Neuschafer-Rube AP, Katz N, Kietzmann T and 
Immenschuh S. (2003): Phorbol ester-dependent activation of peroxiredoxin I 
gene expression via a protein kinase C, Ras, p38 mitogen-activated protein 
kinase signaling pathway. J. Biol. Chem. 278:45419–45434. 
Horwood NJ, Mahon T, McDaid JP, Campbell J, Mano H, Brennan FM, 
Webster D and Foxwell BM. (2003): Bruton's tyrosine kinase is required for 
lipopolysaccharide-induced tumor necrosis factor alpha production. J. Exp.Med. 
197:1603–1611. 
Immenschuh S and Baumgart-Vogt E. (2005): Peroxiredoxins, oxidative stress, and 
cell proliferation. Antioxid. Redox Signal 7:768–777. 
Immenschuh S, Iwahara SI, Satoh H, Nell C, Katz N and Muller-Eberhard U. 
(1995): Expression of the mRNA of heme-binding protein 23 is coordinated with 
that of heme oxygenase-1 by heme and heavy metals in primary rat hepatocytes 
and hepatoma cells. Biochemistry 34:13407–13411. 
Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and 
Yamamoto M. (2000): Transcription factor Nrf2 coordinately regulates a group 
of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275:16023–
16029. 
Karin M, Lawrence T and Nizet V. (2006):  Innate immunity gone awry: linking 
microbial infections to chronic inflammation and cancer. Cell 124: 823–835. 
Kato T, Delhase M, Hoffmann A and Karin M. (2003): CK2 is a C-Terminal 
IkappaB kinase responsible for NF-κB activation during the UV response. 
Mol.Cell 12: 829–839. 
Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C, Han J, Agarwal A and 
Kong A. N. (2006): Mechanism of action of sulforaphane: inhibition of p38 
mitogen-activated protein kinase isoforms contributing to the induction of 
antioxidant response element-mediated heme oxygenase-1 in human hepatoma 
HepG2 cells. Cancer Res. 66: 8804-8813. 
References 
 
25 
 
Kim YJ, Ahn JY, Liang P, Clement Ip, Zhang Y and Park YM. (2007):  
Human prx1 Gene Is a Target of Nrf2 and Is Up-regulated by 
Hypoxia/Reoxygenation: Implication to Tumor Biology. Cancer Res. 67: 546-
554. 
Kisucka J, Chauhan AK, Patten IS, Yesilaltay A, Neumann C, Van Etten RA, 
Krieger M and Wagner DD. (2008): Peroxiredoxin1 prevents excessive 
endothelial activation and early atherosclerosis. Circ. Res.103:598-605. 
 Li B, Ishii T, Tan CP, Soh J W and Goff SP. (2002): Pathways of induction of 
peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein 
kinase and protein kinase C. J. Biol. Chem. 277:12418–12422. 
Maines M. D. (1997). The heme oxygenase system: a regulator of second messenger 
gases. Annu. Rev. Pharmacol. Toxicol. 37: 517–554. 
Muraosa Y and Shibahara S. (1993). Identification of a cis-regulatory element and 
putative trans-acting factors responsible for 12-O-tetradecanoylphorbol-13-
acetate (TPA)-mediated induction of heme oxygenase expression in 
myelomonocytic cell lines. Mol. Cell. Biol. 13: 7881–7891. 
Naidu S, Wijayanti N, Santoso S, Kietzmann T and Immenschuh S. (2008): An 
atypical NF-kappaB-regulated pathway mediates phorbol ester-dependent heme 
oxygenase-1 gene activation in monocytes. J. Immunol. 181: 4113-4123 
Neumann CA and Fang Q. (2007): Are peroxiredoxins tumor suppressors? Current 
Opinion in Pharmacology. 7:375–380. 
Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, 
Bronson RT, Fujiwara Y, Orkin SH and Van Etten RA. (2003): Essential role 
for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour 
suppression. Nature 424:561–565. 
Nguyen T, Sherratt PJ and Pickett CB. (2003): Regulatory mechanisms controlling 
gene expression mediated by the antioxidant response element. Annu. Rev. 
Pharmacol. Toxicol. 43: 233-260.  
Otterbein LE, Soares MP, Yamashita K and Bach FH. (2003): Heme oxygenase-1: 
unleashing the protective properties of heme. Trends Immunol. 24:449-55. 
 
References 
 
26 
 
Park HS, Jung HY, Park EY, Kim J, Lee WJ and Bae YS. (2004): Cutting edge: 
Direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for 
lipopolysaccharide-induced production of reactive oxygen species and activation 
of NF-κB. J. Immunol. 173:3589–3593 
Poss KD and Tonegawa S. (1997). Reduced stress defense in heme oxygenase 1-
deficient cells. Proc. Natl. Acad. Sci. 94:10925–10930. 
Rhee SG, Chaeb HZ and Kim K. (2005): Peroxiredoxins: A historical overview and 
speculative preview of novel mechanisms and emerging concepts in cell 
signaling. Free Radic. Biol. Med. 38:1543–1552. 
Richard B and Johnston Jr. (1988): Monocytes and macrophages. N. Engl. J. med. 
318: 747-751 
Ryter SW, Alam J and Choi AM. (2006): Heme oxygenase-1/carbon monoxide: 
From basic science to therapeutic applications. Physiol. Rev. 86:583– 650. 
Sambrook J, Fritsch EF and Maniatis T. Molecular Cloning. 2nd ed. (1989) New 
York, NY: Cold Spring Harbor Laboratory Press. 
Singh RP, Dhawan P, Golden C, Kapoor GS and Mehta KD. (1999): One-way 
cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) 
induces low density lipoprotein receptor expression through activation of the 
p42/44(MAPK) cascade. J. Biol. Chem. 274: 19593-19600. 
Takada YA, Mukhopadhyay GC, Kundu G, Mahabeleshwar H, Singh S and 
Aggarwal BB. (2003): Hydrogen peroxide activates NF-κB through tyrosine 
phosphorylation of IκBα and serine phosphorylation of p65: evidence for the 
involvement of IαBαkinase and Syk protein-tyrosine kinase. J. Biol. Chem. 
278:24233–24241. 
Tenhunen R, Marver HS and Schmid R. (1968): The enzymatic conversion of 
heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. 61:748–
755. 
Tracz MJ, Juncos JP, Grande JP, Croatt AJ, Ackerman AW, Rajagopalan G, 
Knutson KL, Badley AD, Griffin MD, Alam J and Nath KA. (2007): Renal 
hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in      
HO-1-/- mice. Am. J. Pathol. 170: 1820-1830. 
References 
 
27 
 
Wagener FA, da Silva JL, Farley T, de Witte T, Kappas A and Abraham NG. 
(1999): Differential effects of heme oxygenase isoforms on heme mediation of 
endothelial intracellular adhesion molecule 1 expression. J. Pharmacol. Exp. 
Ther. 291:416-23. 
Wijayanti N, Huber S, Samoylenko A, Kietzmann T and Immenschuh S. (2004): 
Role of NF-κB and p38 MAP kinase signaling pathways in the 
lipopolysaccharide- dependent activation of heme oxygenase-1 gene expression. 
Antioxid. Redox Signal. 6: 802–810. 
Wood ZA, Schroder E, Harris R and Poole LB. (2003):  Structure, mechanism and 
regulation of peroxiredoxins. Trends in Biochemical Sciences 28:1.  
Wu WS, Tsai RK, Chang CH, Wang S, Wu JR and Chang YX. (2006): Reactive 
oxygen species mediated sustained activation of protein kinase C alpha and 
extracellular signal-regulated kinase for migration of human hepatoma cell 
HepG2. Mol. Cancer Res. 4: 747-758 
Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara 
Y and Koizumi S. (1999): Oxidative stress causes enhanced endothelial cell 
injury in human heme oxygenase-1 deficiency. J. Clin. Invest. 103:129 –135. 
Yu RS, Mandlekar W, Lei W, Fahl E, Tan TH and Kong AN. (2000): p38 
mitogen-activated protein kinase negatively regulates the induction of phase II 
drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem. 275: 2322-
2327. 
  
 
 
 
 
 
 
Acknowledgements 
 
28 
 
It is difficult to overstate my gratitude to my supervisor, Dr. Stephan 
Immenschuh for his unflinching encouragement and invaluable guidance during the 
entire period of this thesis. His enthusiastic discussions not only answered several of 
my questions, but also inculcated a strong interest towards the subject. He was always 
there with a gentle support through all thicks and thins of my professional and 
personal concerns. I am indebted to him more than he knows. 
A debt of gratitude to Dr. Sentot Santoso, whose timely ideas and valuable 
suggestions helped me solve many problem issues involved during my PhD. I admire 
his resourcefulness and practical approach to science often mingled with rib-tickling 
humor. Talking with him was always a motivating and learning experience. 
 Special thanks go to Professor. Dr. med. Gregor Bein, Director of the Institute 
for Clinical Immunology and Transfusion Medicine, for allowing me to pursue PhD 
studies in the institute. And I also thank secretaries of the institute, Fr. R. Adam and 
Fr. M. Gotz for their help in administrative issues. 
This thesis would not have seen the light without the reliable scholarship from 
the Graduiertenkolleg 534 (GRK 534) supported by the German Research Foundation 
(DFG). I aver my sincere thanks to Dr. Thomas Noll for his great efforts to ensure my 
scholarship for the entire period of PhD. 
I specially thank my colleagues Nastiti Wijayanti and Silke Werth who not only 
introduced various methods to me during the initial stages of my PhD, but also 
extended their friendly support in all of my technical difficulties. Last but not least, I 
thank my “Deutsche mama” Annette Zeyer for her warm love and support during the 
difficult times in the lab. 
A special thought is devoted to my parents and chinnu for their never-ending 
love, support and encouragement. Finally, I wish to thank my cheerful group of 
friends and all well-wishers, who always inspire me with their uncompromised faith 
both in me and my deeds.  
 
Curriculum Vitae 
 
29 
 
Personal data 
Name  : Srivatsava Naidu 
Date of birth : 7 March, 1981  
Place of birth : Andhra Pradesh, India 
Nationality : Indian 
Contact 
Institute for Clinical Immunology and Transfusion Medicine 
Justus-Liebig-University Giessen 
Langhansstr. 7 
35392 Giessen 
Germany 
Tel:  49- (0)17623948202 
 
Education 
2005 – Present: Student of the International PhD program of the Faculties of 
Veterinary-Medicine and Medicine, Justus-Liebig University, 
Giessen, Germany. 
2004 – 2005: Advanced course in bioinformatics, University of Skovde, 
Skovde, Sweden. 
2001 – 2003: Master of Science (M. Sc.) in biotechnology, Andhra 
University, Visakhapatnam, A.P., India. 
Master thesis: The expression, purification and crystallization trials of the 
molecular Chaperonins GroEL and GroES of E.coli. Under Dr. 
S.C. Mande, Structural biology laboratory, Center for DNA 
finger printing and diagonostics (CDFD), Hyderabad, India 
1998 – 2001: Bachelor of Science (B. Sc.), biology and chemistry as majors 
from Andhra University, Visakhapatnam, A.P., India. 
Publications 
 
30 
 
1. Wijayanti, N., S. Naidu, T. Kietzmann and S. Immenschuh. 2008. Inhibition of 
phorbol ester-dependent peroxiredoxin I gene activation by lipopolysaccharide 
via phosphorylation of RelA/p65 at serine 276 in monocytes. Free. Radic. Biol. 
Med. 44: 699-710. 
 
2. Naidu, S., N. Wijayanti, S. Santoso, T. Kietzmann and S. Immenschuh. 2008. An 
atypical NF-kappaB-regulated pathway mediates phorbol ester-dependent heme 
oxygenase-1 gene activation in monocytes. J. Immunol. 181: 4113-4123. 
 
3. Immenschuh, S., S. Naidu, T. Chavakis, H. Beschmann, R. J. Ludwig and S. 
Santoso. Transcriptional induction of Junction adhesion molecule-C gene 
expression in activated T cells. J. leuk. Biol. (Accepted, January 2009) 
 
4. Naidu, S., V. Vijayan, S. Santoso, T. Kietzmann and S. Immenschuh.        
Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 
gene expression via NF-E2-related factor-2 (Nrf2) (Submitted).  
